Zion Oil & Gas (ZNOG) 10-Q 6 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 05, 2024
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity Information [Line Items]
Entity Registrant Name	ZION OIL & GAS, INC.
Entity Central Index Key	0001131312
Entity File Number	001-33228
Entity Tax Identification Number	20-0065053
Entity Incorporation, State or Country Code	DE
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Contact Personnel [Line Items]
Entity Address, Address Line One	12655 N Central Expressway
Entity Address, Address Line Two	Suite 1000
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75243
Entity Phone Fax Numbers [Line Items]
City Area Code	(214)
Local Phone Number	221-4610
Entity Listings [Line Items]
Title of 12(b) Security	N/A
No Trading Symbol Flag	true
Security Exchange Name	NONE
Entity Common Stock, Shares Outstanding		821,982,028

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 2,461	$ 615
Fixed short term bank and escrow deposits – restricted	1,064	1,020
Prepaid expenses and other	710	515
Governmental receivables	117	18
Other receivables	143	123
Total current assets	4,495	2,291
Unproved oil and gas properties, full cost method (see Note 4)	17,815	16,637
Property and equipment at cost
Drilling rig and related equipment, net of accumulated depreciation of $2,447 and $2,215 (see note 2I)	5,017	5,510
Property and equipment, net of accumulated depreciation of $699 and $686	104	74
Property and equipment, net	5,121	5,584
Right of Use Lease Assets (see Note 5)	891	194
Other assets
Assets held for severance benefits	491	475
Total other assets	491	475
Total assets	28,813	25,181
Current liabilities
Accounts payable	983	777
Insurance financing (see note 6D)	232	432
Lease obligation – current (see Note 5)	183	167
Asset retirement obligation	571	571
Accrued liabilities	526	693
Total current liabilities	2,495	2,640
Long-term liabilities
Lease obligation – non-current (see Note 5)	669	24
Provision for severance pay	511	499
Total long-term liabilities	1,180	523
Total liabilities	3,675	3,163
Commitments and contingencies (see Note 6)
Stockholders’ equity
Common stock, par value $.01; Authorized: 1,200,000,000 shares at June 30, 2024: Issued and outstanding: 818,873,764 and 640,002,580 shares at June 30, 2024 and December 31, 2023, respectively	8,189	6,400
Additional paid-in capital	308,319	302,177
Stock subscription receivable	(985)
Accumulated deficit	(290,385)	(286,559)
Total stockholders’ equity	25,138	22,018
Total liabilities and stockholders’ equity	$ 28,813	$ 25,181

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Drilling rig and related equipment, net of accumulated depreciation (in Dollars)	$ 2,447	$ 2,215
Accumulated depreciation (in Dollars)	$ 699	$ 686
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	1,200,000,000	1,200,000,000
Common stock, shares issued	818,873,764	640,002,580
Common stock, shares outstanding	818,873,764	640,002,580

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
General and administrative	$ 1,201	$ 1,271	$ 2,376	$ 2,774
Post impairment of unproved oil and gas properties		48		93
Other	882	1,016	1,481	1,599
Loss from operations	(2,083)	(2,335)	(3,857)	(4,466)
Other income (expense), net
Foreign exchange income (loss)	10	(2)	31	(4)
Financial income (expenses), net	9	3		(3)
Loss, before income taxes	(2,064)	(2,334)	(3,826)	(4,473)
Income taxes
Net loss	$ (2,064)	$ (2,334)	$ (3,826)	$ (4,473)
Net loss per share of common stock
Basic (in Dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted-average shares outstanding
Basic (in Shares)	745,565	542,812	706,294	536,950

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Operations (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Diluted	$ 0	$ 0	$ (0.01)	$ (0.01)
Diluted	745,565	542,812	706,294	536,950

Consolidated Condensed Statem_3

Consolidated Condensed Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($) $ in Thousands	Common Stock	Additional paid-in Capital	Subscription Receivables	Accumulated deficit	Total
Balances at Dec. 31, 2022	$ 5,242	$ 296,460		$ (278,602)	$ 23,100
Balances (in Shares) at Dec. 31, 2022	524,231,000
Funds received from sale of DSPP units and shares and exercise of warrants	$ 360	2,366			2,726
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	36,068,000
Funds received from option exercises	$ 2	10			12
Funds received from option exercises (in Shares)	150,000
Costs associated with the issuance of shares		(173)			(173)
Value of options granted to employees, directors and others as non-cash compensation		658			658
Net loss				(4,473)	(4,473)
Balances at Jun. 30, 2023	$ 5,604	299,321		(283,075)	21,850
Balances (in Shares) at Jun. 30, 2023	560,449,000
Balances at Mar. 31, 2023	$ 5,337	297,582		(280,741)	22,178
Balances (in Shares) at Mar. 31, 2023	533,713,000
Funds received from sale of DSPP units and shares and exercise of warrants	$ 266	1,668			1,934
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	26,711,000
Funds received from option exercises	$ 1	3			4
Funds received from option exercises (in Shares)	25,000
Costs associated with the issuance of shares		(173)			(173)
Value of options granted to employees, directors and others as non-cash compensation		241			241
Net loss				(2,334)	(2,334)
Balances at Jun. 30, 2023	$ 5,604	299,321		(283,075)	21,850
Balances (in Shares) at Jun. 30, 2023	560,449,000
Balances at Dec. 31, 2023	$ 6,400	302,177		(286,559)	$ 22,018
Balances (in Shares) at Dec. 31, 2023	640,002,000				640,002,580
Funds received from sale of DSPP units and shares and exercise of warrants	$ 1,788	7,665	(985)		$ 8,468
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	178,776,000
Funds received from option exercises	$ 1	8			9
Funds received from option exercises (in Shares)	96,000
Costs associated with the issuance of shares		(1,763)			(1,763)
Value of options granted to employees, directors and others as non-cash compensation		232			232
Net loss				(3,826)	(3,826)
Balances at Jun. 30, 2024	$ 8,189	308,319	(985)	(290,385)	$ 25,138
Balances (in Shares) at Jun. 30, 2024	818,874,000				818,873,764
Balances at Mar. 31, 2024	$ 7,094	304,354		(288,321)	$ 23,127
Balances (in Shares) at Mar. 31, 2024	709,445,000
Funds received from sale of DSPP units and shares and exercise of warrants	$ 1,095	4,801	(985)		4,911
Funds received from sale of DSPP units and shares and exercise of warrants (in Shares)	109,404,000
Funds received from option exercises		2			2
Funds received from option exercises (in Shares)	25,000
Costs associated with the issuance of shares		(947)			(947)
Value of options granted to employees, directors and others as non-cash compensation		109			109
Net loss				(2,064)	(2,064)
Balances at Jun. 30, 2024	$ 8,189	$ 308,319	$ (985)	$ (290,385)	$ 25,138
Balances (in Shares) at Jun. 30, 2024	818,874,000				818,873,764

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (3,826)	$ (4,473)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	417	401
Amortization of Right of Use Lease Assets	132	123
Cost of options issued to employees, directors and others as non-cash compensation	232	658
Post impairment of unproved oil and gas properties		93
Capital loss on sale of Property and equipment	62
Change in assets and liabilities, net:
Other deposits		483
Prepaid expenses and other	(195)	206
Governmental receivables	(99)	251
Lease obligation – current and non-current	(168)	(129)
Other receivables	(20)	(15)
Severance payable, net	(4)	(6)
Accounts payable	(238)	(168)
Accrued liabilities	(68)	184
Net cash used in operating activities	(3,775)	(2,392)
Cash flows from investing activities
Acquisition of property and equipment	(43)
Proceeds from sale of property and equipment	31
Acquisition of drilling rig and related equipment	(22)
Investment in unproved oil and gas properties	(848)	(1,729)
Net cash used in investing activities	(882)	(1,729)
Cash flows from financing activities
Proceeds from exercise of stock options	9	12
Costs paid related to the issuance of new shares	(1,930)	(173)
Proceeds from issuance of stock and exercise of warrants	8,468	2,726
Net cash provided by financing activities	6,547	2,565
Net (decrease)/increase in cash, cash equivalents and restricted cash	1,890	(1,556)
Cash, cash equivalents and restricted cash – beginning of period	1,635	3,114
Cash, cash equivalents and restricted cash – end of period	3,525	1,558
Non-cash investing and financing activities:
Unpaid investments in oil & gas properties	992	806
Unpaid Costs associated with the issuance of shares	167
Subscription Receivables	985
Depreciation of oil and gas equipment	10
Addition of right of use lease assets and lease obligations	$ 829

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Statement of Cash Flows [Abstract]
Cash and cash equivalents	$ 2,461	$ 615
Restricted cash included in fixed long-term bank deposits	1,064	1,020
Total restricted cash	$ 3,525	$ 1,635

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Going Concern	6 Months Ended
	Jun. 30, 2024
Nature of Operations, Basis of Presentation and Going Concern [Abstract]
Nature of Operations, Basis of Presentation and Going Concern	Note 1 - Nature of Operations, Basis of Presentation and Going Concern A. Nature of Operations Zion Oil & Gas, Inc., a Delaware corporation (“we,” “our,” “Zion” or the “Company”) is an oil and gas exploration company with a history of 24 years of oil & gas exploration in Israel. As of June 30, 2024, the Company has no revenues from its oil and gas operations. Zion maintains its corporate headquarters in Dallas, Texas. The Company also has branch offices in Caesarea, Israel and Geneva, Switzerland. The purpose of the Israel branch is to support the Company’s operations in Israel, and the purpose of the Switzerland branch is to operate a foreign treasury center for the Company. On January 24, 2020, Zion incorporated a wholly owned subsidiary, Zion Drilling, Inc., a Delaware corporation, for the purpose of owning a drilling rig, related equipment and spare parts, and on January 31, 2020, Zion incorporated another wholly owned subsidiary, Zion Drilling Services, Inc., a Delaware corporation, to act as the contractor providing such drilling services. When Zion is not using the rig for its own exploration activities, Zion Drilling Services may contract with other operators in Israel to provide drilling services at market rates then in effect. Zion has the trademark “ZION DRILLING” filed with the United States Patent and Trademark Office. Zion has the trademark filed with the World Intellectual Property Organization in Geneva, Switzerland, pursuant to the Madrid Agreement and Protocol. In addition, Zion has the trademark filed with the Israeli Trademark Office in Israel. Exploration Rights/Exploration Activities New Megiddo Valleys License 434 (“NMVL 434”) – Megiddo-Jezreel #1 Re-Entry (“MJ-01”) On September 14, 2023, the Israel Ministry of Energy approved a new Megiddo Valleys License 434 (“NMVL 434”), allowing for oil and gas exploration on approximately 75,000 acres or 302 square kilometers. This Exploration License 434 is valid for three years until September 13, 2026 with four potential 1-year extensions for a total of seven years until September 13, 2030. This NMVL 434 effectively supersedes our previous NML 428. On February 21, 2024, members of the Supervisory Committee visited our rig site. During this visit, they interacted with staff from Zion Oil & Gas, and our consultants and potential service providers. Some of these interactions occurred at Kibbutz Sde Eliyahu, while others were conducted through video conferencing with participants from the United States, Europe and the Middle East. Following these discussions, the Committee has officially accepted our work plan for the MJ-01 project. This acceptance allowed us to sign agreements and secure mobilization dates with our service providers required to commence and complete the project. Field operations remain on schedule, and our rig is now positioned over the MJ-01 wellbore. Repairs and maintenance, as well as the inspection of the rig, have all been completed successfully. All necessary wireline equipment for the project has been mobilized with additional essential items from India, China, Romania and Greece currently in transit for the final stages of operation. The initial phase of the MJ-01 recompletion project involves drilling out the plugs and nearly 625 meters (approximately 2,050 feet) of cement in the well. Following the drilling out of the cement plugs, we will next run a series of wireline tests and casing integrity tests to ensure that the wellbore has withstood the past six years of high temperatures. The next phase of the MJ-01 recompletion project, provided all goes as expected from the initial phase, involves perforating, stimulating and well testing previously identified zones of interest. B. Basis of Presentation The accompanying unaudited interim consolidated condensed financial statements of Zion Oil & Gas, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with Article 8-03 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring accruals necessary for a fair statement of financial position, results of operations and cash flows, have been included. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the operating results for the year ending December 31, 2024 or for any other subsequent interim period. C. Going Concern The Company incurs cash outflows from operations, and all exploration activities and overhead expenses to date have been financed by way of equity or debt financing. The recoverability of the costs incurred to date is uncertain and dependent upon achieving significant commercial production of hydrocarbons. The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to undertake further exploration and development activities and ultimately generating profitable operations from its oil and natural gas interests in the future. The Company’s current operations are dependent upon the adequacy of its current assets to meet its current expenditure requirements and the accuracy of management’s estimates of those requirements. Should those estimates be materially incorrect, the Company’s ability to continue as a going concern may be in doubt. The consolidated condensed financial statements have been prepared on a going concern basis, which contemplates realization of assets and liquidation of liabilities in the ordinary course of business. During the six months ended June 30, 2024, the Company incurred a net loss of approximately $3.8 million and had an accumulated deficit of approximately $290 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date the financials were issued. To carry out planned operations, the Company must raise additional funds through additional equity and/or debt issuances or through profitable operations. There can be no assurance that this capital or positive operational income will be available to the Company, and if it is not, the Company may be forced to curtail or cease exploration and development activities. The consolidated condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 - Summary of Significant Accounting Policies A. Net Loss per Share Data Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share for 2024 as the inclusion of 26,940,575 in stock options and 29,456,952 in warrants would be anti-dilutive. Diluted net loss per share is the same as basic net loss per share for 2023 as the inclusion of 21,286,250 in stock options and 31,701,977 in warrants would be anti-dilutive. B. Use of Estimates The preparation of the accompanying unaudited consolidated condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases, accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, political instability and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated condensed financial statements in future periods. During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed. Similar uncertainties are posed by the Israel-Hamas war and its duration and whether the war expands regionally to include other hostile parties. It is important to note that Zion’s license area is not located near current combat zone. Actual results may differ from these estimates. C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the three and six months ended June 30, 2024, the Company did not record any post-impairment charges. During the three and six months ended June 30, 2023, the Company recorded post-impairment charges of $48,000 and $93,000, respectively. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $17,815,000 and $16,637,000 as of June 30, 2024 and December 31, 2023, respectively. D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, other receivables. accounts payable and accrued liabilities, are carried at historical cost. At June 30, 2024, and December 31, 2023, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. E. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated condensed financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. F. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity G. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report. H. Recently Adopted Accounting Pronouncements The Company does not believe that the adoption of any recently issued accounting pronouncements in 2024 had a significant impact on our consolidated condensed financial position, results of operations, or cash flow. I. Depreciation and Accounting for Drilling Rig and Related Equipment On March 12, 2020, Zion purchased an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion is depreciating the rig on a straight-line basis. Zion uses the First In First Out (“FIFO”) method of accounting for the spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly. Zion purchased rig spare parts totaling approximately $22,000 during the second quarter of 2024 in preparation for its MJ-01 re-entry project. Zion sold some excess scrap drilling pipe and accessories for approximately $30,000 to a local Israeli party during the second quarter of 2024. This transaction triggered a reduction in Other Drilling Assets, an accumulated depreciation adjustment and a loss on the disposal. See the table below for a reconciliation of the rig-related activity during the quarter ended June 30, 2024: I-35 Drilling Rig & Associated Equipment: Six-month period ended June 30, 2024 I-35 Rig Other Total US$ US$ US$ US$ December 31, 2023 4,591 608 311 5,510 Asset Additions - 22 - 22 Asset Depreciation (318 ) - (96 ) (414 ) Asset Disposals - - (93 ) (93 ) Asset Disposals for Self-Consumption - (8 ) - (8 ) June 30, 2024 4,273 622 122 5,017

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2024
Stockholders’ Equity [Abstract]
Stockholders' Equity	Note 3 - Stockholders’ Equity The Company’s shareholders approved the amendment of the Company’s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock, par value $0.01, that the Company is authorized to issue from 800,000,000 shares to 1,200,000,000 shares, effective June 7, 2023. A. 2021 Omnibus Incentive Stock Option Plan Effective June 9, 2021, the Company’s shareholders authorized the adoption of the Zion Oil & Gas, Inc. 2021 Omnibus Incentive Stock Option Plan (“Omnibus Plan”) for employees, directors and consultants, initially reserving for issuance thereunder 38,000,000 shares of common stock. The Omnibus Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock, bonus stock, awards in lieu of cash obligations, other stock-based awards and performance units. The plan also permits cash payments under certain conditions. The compensation committee of the Board of Directors (comprised of independent directors) is responsible for determining the type of award, when and to whom awards are granted, the number of shares and the terms of the awards and exercise prices. The options are exercisable for a period not to exceed ten years from the date of grant. During the six months ended June 30, 2024, the Company granted the following options from the Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 175,000 shares of Common Stock to five senior officers and two staff members at an exercise price of $0.07 per share. The options vested upon grant and are exercisable through January 4, 2034. The fair value of the options at the date of grant amounted to approximately $11,000. ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2034. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $1,800. During the six months ended June 30, 2023, the Company granted the following options from the Omnibus Plan for employees, directors and consultants, to purchase shares of common stock as non-cash compensation: i. Options to purchase 175,000 shares of Common Stock to five senior officers and one staff member at an exercise price of $0.0615 per share. The options vested upon grant and are exercisable through January 4, 2033. The fair value of the options at the date of grant amounted to approximately $9,000. ii. Options to purchase 25,000 shares of Common Stock to one senior officer at an exercise price of $0.01 per share. The options vested upon grant and are exercisable through January 4, 2033. These options were granted per the provisions of the Israeli Appendix to the Plan. The fair value of the options at the date of grant amounted to approximately $1,500. iii. Options to purchase 25,000 shares of Common Stock to one board member, at an exercise price of $0.07 per share. The options vested upon grant and are exercisable through June 8, 2033. The fair value of the options at the date of grant amounted to approximately $1,500. B. Stock Options The stock option transactions since January 1, 2024 are shown in the table below: Number of Weighted US$ Outstanding, December 31, 2023 34,091,250 0.23 Changes during 2024 to: Granted to employees, officers, directors and others 200,000 0.07 Expired/Cancelled/Forfeited (250,000 ) 2.31 Exercised (95,675 ) 0.09 Outstanding, June 30, 2024 33,945,575 0.22 Exercisable, June 30, 2024 26,940,575 0.25 The following table summarizes information about stock options outstanding as of June 30, 2024: Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number Weighted Weighted Range of Number Weighted Weighted US$ US$ US$ US$ 0.07 7,005,000 9.48 0.07 — — — — — — — — 0.01 5,000 0.20 0.01 — — — — 0.01 20,000 2.18 0.01 — — — — 0.01 130,000 2.76 0.01 — — — — 0.01 50,000 2.76 0.01 — — — — 0.01 60,000 3.05 0.01 — — — — 0.01 200,000 3.14 0.01 — — — — 0.01 40,000 3.50 0.01 — — — — 0.01 70,000 3.76 0.01 — — — — 0.01 25,000 3.76 0.01 — — — — 0.01 30,000 3.92 0.01 — — — — 0.01 4,000 4.02 0.01 — — — — 0.01 25,000 4.77 0.01 — — — — 0.01 35,000 5.47 0.01 — — — — 0.01 150,000 5.64 0.01 — — — — 0.01 35,000 5.77 0.01 — — — — 0.01 75,000 6.77 0.01 — — — — 0.01 200,000 7.14 0.01 — — — — 0.01 300,000 7.30 0.01 — — — — 0.01 10,000 7.42 0.01 — — — — 0.01 500,000 7.77 0.01 — — — — 0.01 55,000 7.80 0.01 — — — — 0.01 960,000 8.05 0.01 — — — — 0.01 75,000 8.37 0.01 — — — — 0.01 10,000 8.43 0.01 — — — — 0.01 795,000 8.49 0.01 — — — — 0.01 25,000 8.77 0.01 — — — — 0.01 10,000 9.43 0.01 — — — — 0.01 895,000 9.48 0.01 — — — — 0.01 25,000 9.77 0.01 — — — — 0.06 50,000 8.77 0.06 — — — — 0.07 125,000 9.77 0.07 — — — — 0.14 240,000 7.80 0.14 — — — — 0.15 3,200,000 7.77 0.15 — — — — 0.15 6,389,325 8.05 0.15 — — — — 0.16 340,000 1.70 0.16 — — — — 0.16 75,000 5.70 0.16 — — — — 0.18 25,000 1.67 0.18 — — — — 0.18 5,155,000 8.49 0.18 — — — — 0.24 25,000 8.34 0.24 — — — — 0.24 118,000 8.37 0.24 — — — — 0.25 50,000 7.42 0.25 — — — — 0.25 363,000 7.42 0.25 — — — — 0.28 25,000 1.43 0.28 — — — — 0.28 25,000 5.43 0.28 — — — — 0.29 25,000 3.21 0.29 — — — — 0.39 1,435,000 7.28 0.39 — — — — 0.59 1,400,000 3.14 0.59 — — — — 0.59 1,600,000 7.14 0.59 — — — — 0.92 350,000 2.76 0.92 — — — — 0.92 550,000 6.77 0.92 — — — — 1.38 105,307 0.76 1.38 — — — — 1.67 405,943 0.50 1.67 — — — — 1.78 25,000 0.43 1.78 — — — — 4.15 25,000 0.25 4.15 0.07 7,005,000 0.07 0.01-4.15 26,940,575 0.25 Granted to employees The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the 2024 2023 Weighted-average fair value of underlying stock at grant date $ 0.07 $ 0.06 Dividend yields — — Expected volatility 133 % 136%-137 % Risk-free interest rates 3.97 % 3.87%-3.85 % Expected lives (in years) 5.00 5.00 Weighted-average grant date fair value $ 0.07 $ 0.06 C. Compensation Cost for Warrant and Option Issuances The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors: For the three months ended June 30, 2024 2023 US$ thousands US$ thousands 109 242 For the six months ended June 30, 2024 2023 US$ thousands US$ thousands 230 656 The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees: For the three months ended June 30, 2024 2023 US$ thousands US$ thousands 1 — For the six months ended June 30, 2024 2023 US$ thousands US$ thousands 2 2 The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: For the three months ended June 30, 2024 2023 US$ thousands US$ thousands — — For the six months ended June 30, 2024 2023 US$ thousands US$ thousands — — As of June 30, 2024, there was $101,000 of unrecognized compensation cost related to non-vested stock options granted under the Company’s various stock option plans. That cost is expected to be recognized during 2024. D. Dividend Reinvestment and Stock Purchase Plan (“DSPP”) On March 13, 2014 Zion filed a registration statement on Form S-3 that was part of a replacement registration statement that was filed with the SEC using a “shelf” registration process. The registration statement was declared effective by the SEC on March 31, 2014. On February 23, 2017, the Company filed a Form S-3 with the SEC (Registration No. 333-216191) as a replacement for the Form S-3 (Registration No. 333-193336), for which the three-year period ended March 31, 2017, along with the base Prospectus and Supplemental Prospectus. The Form S-3, as amended, and the new base Prospectus became effective on March 10, 2017, along with the Prospectus Supplement that was filed and became effective on March 10, 2017. The Prospectus Supplement under Registration No. 333-216191 describes the terms of the DSPP and replaces the prior Prospectus Supplement, as amended, under the prior Registration No. 333-193336. On September 15, 2020, the Company extended the termination date of the ZNWAD Warrant by two (2) years from the expiration date of May 2, 2021 to May 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of May 2, 2023, any outstanding ZNWAD warrants expired. On September 15, 2020, the Company extended the termination date of the ZNWAE Warrant by two (2) years from the expiration date of May 1, 2021 to May 1, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of May 1, 2023, any outstanding ZNWAE warrants expired. On September 15, 2020, the Company extended the termination date of the ZNWAF Warrant by two (2) years from the expiration date of August 14, 2021 to August 14, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of August 14, 2023, any outstanding ZNWAF warrants expired. On December 14, 2022, the Company extended the termination date of the ZNWAG warrant by one (1) year from the expiration date of January 8, 2023 to January 8, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of January 8, 2024, any outstanding ZNWAG warrants expired. On September 15, 2020, the Company extended the termination date of the ZNWAH Warrant by two (2) years from the expiration date of April 2, 2021 to April 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of April 2, 2023, any outstanding ZNWAH warrants expired. On September 15, 2020, the Company extended the termination date of the ZNWAJ Warrant by two (2) years from the expiration date of October 29, 2021 to October 29, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On October 29, 2023, any outstanding ZNWAJ warrants expired. On September 15, 2020, the Company extended the termination date of the ZNWAK warrant by two (2) years from the expiration date of February 25, 2021 to February 25, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of February 25, 2023, any outstanding ZNWAK warrants expired. On September 15, 2020, the Company extended the termination date of the ZNWAL Warrant by two (2) years from the expiration date of August 26, 2021 to August 26, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. As of August 26, 2023, any outstanding ZNWAL warrants expired. Under our Plan, the Company under a Request For Waiver Program executed Waiver Term Sheets of a unit option program consisting of a Unit (shares of stock and warrants) of its securities and subsequently an option program consisting of shares of stock to a participant. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAM.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants became exercisable on January 15, 2021 and continue to be exercisable through July 15, 2022. On March 21, 2022, the Company extended the termination date of the ZNWAM warrant by one (1) year from the expiration date of July 15, 2022 to July 15, 2023 and revised the exercise price to $0.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On June 16, 2023, the Company extended the termination date of the ZNWAM warrant from July 15, 2023 to September 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2023, the Company extended the termination date of the ZNWAM warrant from September 6, 2023 to October 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On October 19, 2023, the Company extended the termination date of the ZNWAM warrant from October 31, 2023 to December 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 18, 2023, the Company extended the termination date of the ZNWAM warrant from December 31, 2023 to March 31, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On March 28, 2024, the Company extended the termination date of the ZNWAM warrant from March 31, 2024 to December 31, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. The ZNWAN warrants became exercisable on May 16, 2021 and continue to be exercisable through May 16, 2023 at a per share exercise price of $1.00. As of May 16, 2023, any outstanding ZNWAN warrants expired. The ZNWAO warrants became exercisable on June 12, 2021 and continue to be exercisable through June 12, 2023 at a per share exercise price of $.25. As of June 12, 2023, any outstanding ZNWAO warrants expired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a program consisting of Zion securities to a participant. After conclusion of the program on June 17, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet for a unit program consisting of a Unit (shares of stock and warrants) to a participant. After conclusion of the program on May 28, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant has the company notation of “ZNWAP.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants were issued and became exercisable on June 2, 2021 and continue to be exercisable through June 2, 2022 at a per share exercise price of $.25. On March 21, 2022, the Company extended the termination date of the ZNWAP Warrant by one (1) year from the expiration date of June 2, 2022 to June 2, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. During the second quarter of 2022, all warrants represented by ZNWAP and ZNWAR were exercised resulting in a net cash inflow of approximately $365,000. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAQ.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants were issued on May 5, 2022 and were exercisable through July 15, 2023 at a revised per share exercise price of $.05. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On June 16, 2023, the Company extended the termination date of the ZNWAQ warrant from July 15, 2023 to September 6, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On August 21, 2023, the Company extended the termination date of the ZNWAQ warrant from September 6, 2023 to October 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On October 19, 2023, the Company extended the termination date of the ZNWAQ warrant from October 31, 2023 to December 31, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On December 18, 2023, the Company extended the termination date of the ZNWAQ warrant from December 31, 2023 to March 31, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. On March 28, 2024, the Company extended the termination date of the ZNWAQ warrant from March 31, 2024 to December 31, 2024. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on June 18, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAR.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants were issued and became exercisable on June 22, 2021 and continued to be exercisable through June 22, 2022 at a per share exercise price of $.25. Additionally, Zion incurred $115,000 during 2021 in equity issuance costs to an outside party related to this waiver program. On March 21, 2022, the Company extended the termination date of the ZNWAR Warrant by one (1) year from the expiration date of June 22, 2022 to June 22, 2023. Zion considers this warrant as permanent equity per ASC 815-40-35-2. As such, there is no value assigned to this extension. During the second quarter of 2022, all warrants represented by ZNWAP and ZNWAR were exercised resulting in a net cash inflow of approximately $365,000. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on November 15, 2021, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and warrants that will be acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $1.00. The warrant shall have the company notation of “ZNWAS.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a revised per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on September 30, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAT.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants will be issued and become exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a unit program consisting of units of shares of stock and warrants to a participant. After conclusion of the program on December 31, 2022, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $.25. The warrant shall have the company notation of “ZNWAU.” The warrants will not be registered for trading on the OTCQB or any other stock market or trading market. The warrants will be issued and exercisable on November 15, 2025 and continue to be exercisable through December 31, 2025 at a per share exercise price of $.25. Under our Plan, the Company under a Request For Waiver Program executed a Waiver Term Sheet of a program consisting of shares of stock to a participant. After conclusion of the program on August 31, 2023, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. Zion incurred $173,000 in equity issuance costs to an outside party related to this waiver program. The Company executed two additional Waiver Term Sheets with a participant consisting of shares of stock. After conclusion of the program on December 31, 2023, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. During the year ended December 31, 2023, Zion incurred $1,120,000 in equity issuance costs. On January 1, 2024, the Company executed a Waiver Term Sheet with a participant consisting of shares of stock. After conclusion of the program on March 31, 2024, the participant’s Plan account was credited with the number of shares of the Company’s Common Stock that were acquired. During the three and six months ended June 30, 2024, Zion incurred $947,000 and $1,763,000 in equity issuance costs. During the three and six months ended June 30, 2023, Zion incurred $173,000 and $173,000 in equity issuance costs. On April 1, 2024, the Company executed its latest Waiver Term Sheet with a participant consisting of shares of stock. This latest Waiver Term Sheet terminates at the earlier of: (a) a maximum purchase of $10,000,000 through the DSPP, (b) October 1, 2024 or (c) the closing price of Zion’s stock is 15 cents per share for five (5) consecutive days. This latest Waiver Term Sheet remains in effect as none of the criteria listed above have been met. During 2024, one participant who participated in the “Request for Waiver” aspect of the DSPP contributed approximately 56% of the net cash raised through the DSPP . During 2023, one participant who participated in the “Request for Waiver” aspect of the DSPP contributed approximately 54% of the net cash raised through the DSPP. On March 13, 2023, Zion filed with the Securities and Exchange Commission an Amendment No. 2 to the Prospectus Supplement dated as of December 15, 2021 and accompanying base prospectus dated December 1, 2021 relating to the Company’s Dividend Reinvestment and Direct Stock Purchase Plan. The Prospectus forms a part of the Company’s Registration Statement on Form S-3 (File No. 333-261452), as amended, which was declared effective by the SEC on December 15, 2021. Amendment No. 2 – New Unit Option under the Unit Program Under our Plan, we provided a Unit Option under Amendment No. 2. Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 2 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option had up to three tranches of investment, in which the second and third tranches were each subject to termination upon a total of $7,500,000 received from participants by the Company during the first or second tranche. The first tranche period began on March 13, 2023 and terminated on March 26, 2023. The second tranche began on March 27, 2023 and terminated on April 9, 2023 and the third tranche began on April 10, 2023 and terminated on April 27, 2023. The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the OTCQB on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional five hundred (500) shares of Common Stock at a per share exercise price of $0.05. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.05. The warrant shall have the Company notation of “ZNWAV” under the first tranche, “ZNWAW” under the second tranche and “ZNWAX” under the third tranche. Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month, received an additional fifty (50) warrants at an exercise price of $0.05 during this Unit Option Program. The fifty (50) additional warrants were for enrolling into the AMI program and shall have the Company notation of “ZNWAY.” Existing subscribers to the AMI were entitled to the additional fifty (50) warrants, if they purchased at least one (1) Unit during the Unit program. Plan participants, who enrolled in the AMI at a minimum of $100 per month, received one hundred (100) ZNWAY warrants. Plan participants, who enrolled in the AMI at a minimum of $250 per month, received two hundred and fifty (250) ZNWAY warrants. Plan participants, who enrolled in the AMI at a minimum of $500 per month, received five hundred (500) ZNWAY warrants. The AMI program required 90 days of participation to receive the ZNWAY warrants. Existing AMI participants were entitled to participate in this monthly program by increasing their monthly amount above the minimum $50.00 per month. The ZNWAV warrants became exercisable on March 31, 2023 and continued to be exercisable through June 28, 2023 at a per share exercise price of $0.05. As of June 28, 2023, any outstanding ZNWAV warrants expired. The ZNWAW warrants became exercisable on April 14, 2023 and continued to be exercisable through July 13, 2023 at a per share exercise price of $0.05. As of July 13, 2023, any outstanding ZNWAW warrants expired. The ZNWAX warrants became exercisable on May 2, 2023 and continued to be exercisable through July 31, 2023 at a per share exercise price of $0.05. On July 31, 2023, any outstanding ZNWAX warrants expired. The ZNWAY warrants became exercisable on June 12, 2023 and continued to be exercisable through September 10, 2023 at a per share exercise price of $0.05. On September 10, 2023, any outstanding ZNWAY warrants expired. Amendment No. 3 – New Unit Option under the Unit Program Under our Plan, we provided a Unit Option under Amendment No. 3. This Unit Option period began on May 15, 2023 and terminated on June 15, 2023. Our Unit Program consisted of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1 and Amendment No.2. Amendment No. 3 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. As mentioned above, this Unit Option began on May 15, 2023 and terminated on June 15, 2023. The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the OTCQB on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional two hundred (200) shares of Common Stock at a per share exercise price of $0.25. The participant’s Plan account was credited with the number of shares of the Company’s Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.25. The warrant shall have the Company notation of “ZNWAZ” and will not be registered for trading on the OTCQB or any other stock market or trading market. Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enrolled in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $50.00 per month, received an additional three hundred (300) warrants at an exercise price of $0.25 during this Unit Option Program. The three hundred (300) additional warrants were for enrolling into the AMI program and received the above warrant with the Company notation of “ZNWAZ.” Existing subscribers to the AMI were entitled to the additional three hundred (300) warrants, if they purchased at least one (1) Unit during the Unit program. The ZNWAZ warrants became exercisable on July 17, 2023 and continued to be exercisable through July 17, 2024 at a per share exercise price of $0.25. On July 17, 2024, any outstanding ZNWAZ warranted expired. Amendment No. 4 – New Unit Option under the Unit Program Under our Plan, we provided a Unit Option under our Unit Program with this Amendment No. 4. This Unit Option period began on November 6, 2023 and was scheduled to terminate on December 31, 2023. See Amendment No 5 below for data on an extension. Our Unit Program consists of the combination of Common Stock and warrants with basic Unit Program features, conditions and terms outlined in the Original Prospectus Supplement and Amendment No. 1. Amendment No. 4 provided the option period, unit price and the determination of the number of shares of Common Stock and warrants per unit. This Unit Option began on November 6, 2023 and terminated on December 31, 2023. The Unit Option consisted of Units of our securities where each Unit (priced at $250.00 each) was comprised of (i) a certain number of shares of Common Stock determined by dividing $250.00 (the price of one Unit) by the average of the high and low sale prices of the Company’s publicly traded common stock as reported on the OTCQB on the Unit Purchase Date and (ii) Common Stock purchase warrants to purchase an additional fifty (50) shares of Common Stock at a per share exercise price of $0.25. The participant’s Plan account will be credited with the number of shares of the Company’s Common Stock and Warrants that were acquired under the Units purchased. Each warrant affords the participant the opportunity to purchase one share of our Common Stock at a warrant exercise price of $0.25. The warrant shall have the Company notation of “ZNWBA” and will not be registered for trading on the OTCQB or any other stock market or trading market. Plan participants, who enrolled into the Unit Program with the purchase of at least one Unit and enroll in the separate Automatic Monthly Investments (“AMI”) program at a minimum of $ 50.00 The ZNWBA warrants became exercisable on January 15, 2024, and continue to be exercisable through January 15, 2025, unless extended, at a per share exercise price of $0.25. See Amendment No. 5 below for new dates. Amendment No. 5 – Extension of Termination Date to January 31, 2024 Under our Dividend Reinvestment and Common Stock Purchase Plan (the “Plan”), we extended the c

Unproved Oil and Gas Properties

Unproved Oil and Gas Properties, Full Cost Method	6 Months Ended
	Jun. 30, 2024
Unproved Oil and Gas Properties, Full Cost Method [Abstract]
Unproved Oil and Gas Properties, Full Cost Method	Note 4 - Unproved Oil and Gas Properties, Full Cost Method Unproved oil and gas properties, under the full cost method, are comprised as follows: June 30, December 31, US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 3,185 2,538 Capitalized salary costs 2,495 2,444 Capitalized interest costs 1,418 1,418 Legal and seismic costs, license fees and other preparation costs 10,678 10,198 Other costs 39 39 17,815 16,637 Post Impairment of unproved oil and gas properties comprised as follows: For the three months ended For the six months ended 2024 2023 2024 2023 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs - 44 - 55 Capitalized salary costs - - - - Capitalized interest costs - - - - Legal costs, license fees and other preparation costs - 4 - 38 Other costs - - - - - 48 - 93 Changes in Unproved oil and gas properties during the three and six months ended June 30, 2024 and 2023 are as follows: For the three months ended For the six months ended 2024 2023 2024 2023 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 593 82 647 145 Capitalized salary costs 25 26 51 52 Capitalized interest costs - - - - Legal costs, license fees and other preparation costs 254 74 480 198 Other costs - - - - Impairment of unproved oil and gas properties - (48 ) - (93 ) *872 *134 *1,178 *302 * Inclusive of non-cash amounts of approximately $338,000, and $709,000 during the three months ended June 30, 2024, and 2023, respectively * Inclusive of non-cash amounts of approximately $1,002,000, and $806,000 during the six months ended June 30, 2024, and 2023, respectively Please refer to Footnote 1 – Nature of Operations and Going Concern for more information about Zion’s exploration activities.

Right of Use Lease Assets and L

Right of Use Lease Assets and Lease Obligations	6 Months Ended
	Jun. 30, 2024
Right of Use Lease Assets and Lease Obligations [Abstract]
Right of use lease assets and lease obligations	Note 5 - Right of use lease assets and lease obligations The Company is a lessee in several non-cancellable operating leases for transportation and office space. The table below presents the operating lease assets and liabilities recognized on the balance sheet as of June 30, 2024 and December 31, 2023: June 30, December 31, US$ US$ Operating lease assets $ 891 $ 194 Operating lease liabilities: Current operating lease liabilities $ 183 $ 167 Non-current operating lease liabilities $ 669 $ 24 Total operating lease liabilities $ 852 $ 191 The depreciable lives of operating lease assets and leasehold improvements are limited by the expected lease term. The Company’s leases generally do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring operating lease liabilities. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease within a particular currency environment. The Company used incremental borrowing rates as of January 1, 2019 for operating leases that commenced prior to that date. The Company’s field office in Caesarea, Israel is under lease for 6,566 square feet. The Company had an option to renew the lease for another five years from February 1, 2024 to January 31, 2029, provided it is not in breach of the agreement, where it is required as well to furnish a notice of intent to exercise the option six months prior to termination of lease, and it furnishes a bank guarantee and insurance confirmation prior to commencement of the option period. The Company exercised the option to renew the lease for another seven years from February 1, 2024 through January 31, 2031, when rent is to be paid on a monthly basis in the base amount of approximately NIS 46,500 per month (approximately $12,400) at the exchange rate in effect on the date of this report and is linked to an increase (but not a decrease) in the CPI. The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of June 30, 2024 are: June 30, Weighted average remaining lease term (years) 5.9 Weighted average discount rate 7.7 % The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of June 30, 2024: US$ 2024 118 2025 153 2026 150 2027 147 2028 147 Thereafter 350 Total undiscounted future minimum lease payments 1,065 Less: portion representing imputed interest (213 ) Total undiscounted future minimum lease payments 852 Operating lease costs were $74,000 and $149,000 for the three and six months ended June 30, 2024, respectively. Operating lease costs were $57,000 and $126,000 for the three and six months ended June 30, 2023, respectively. Operating lease costs are included within general and administrative expenses on the statements of operations. Cash paid for amounts included in the measurement of operating lease liabilities was $80,000 and $168,000 for the three and six months ended June 30, 2024, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $57,000 and $129,000 for the three and six months ended June 30, 2023, respectively These amounts are included in operating activities in the statements of cash flows. Right-of-use assets obtained in exchange for new operating lease liabilities were $ nil Right-of-use assets obtained in exchange for new operating lease liabilities were $ nil nil

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 6 - Commitments and Contingencies A. Litigation From time to time, the Company may be subject to routine litigation, claims or disputes in the ordinary course of business. The Company defends itself vigorously in all such matters. However, we cannot predict the outcome or effect of any of the potential litigation, claims or disputes. The Company is not subject to any litigation at the present time. B. Market Conditions – Coronavirus, Israel-Hamas War and Russia-Ukraine War During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed. On October 7, 2023, Hamas, a militant terrorist organization in Gaza, infiltrated southern Israel, killing and injuring at least one thousand Israeli citizens. Roughly 250 Israeli hostages were then taken back to Gaza. This unprovoked attack led the nation of Israel to declare war on Hamas approximately one week later. As of the date of this report, Israel remains at war and there are daily battles inside the Gaza strip. Israel’s stated goals are to completely dismantle the terror infrastructure of Gaza, including its extensive tunnel network and to bring back safely all of the hostages. There is uncertainty as to how long the war inside the Gaza strip will last and whether the war will expand to other hostile parties in the region. While we acknowledge that uncertainty and its potential adverse effects on Zion’s business, the Company is moving forward with its re-completion activities at the MJ-01 wellsite. It is important to note that Zion’s license area is not located near any current combat zones. Due to Russia’s invasion of Ukraine, which began in February 2022, and the resulting sanctions and other actions against Russia and Belarus, there has been uncertainty and disruption in the global economy. Although the Russian war against Ukraine did not have a material adverse impact on the Company’s financial results for the quarter ended June 30, 2024, at this time the Company is unable to fully assess the aggregate impact the Russian war against Ukraine will have on its business due to various uncertainties, which include, but are not limited to, the duration of the war, the war’s effect on the global economy, future energy pricing, its impact to the businesses of the Company’s, and actions that may be taken by governmental authorities related to the war. C. Environmental and Onshore Licensing Regulatory Matters The Company is engaged in oil and gas exploration and production and may become subject to certain liabilities as they relate to environmental clean-up of well sites or other environmental restoration procedures and other obligations as they relate to the drilling of oil and gas wells or the operation thereof. Various guidelines have been published in Israel by the State of Israel’s Petroleum Commissioner and Energy and Environmental Ministries as it pertains to oil and gas activities. Mention of these older guidelines was included in previous Zion filings. The Company believes that these regulations will result in an increase in the expenditures associated with obtaining new exploration rights and drilling new wells. The Company expects that an additional financial burden could occur as a result of requiring cash reserves that could otherwise be used for operational purposes. In addition, these regulations are likely to continue to increase the time needed to obtain all of the necessary authorizations and approvals to drill and production test exploration wells. As of June 30, 2024, and December 31, 2023, the Company accrued $ nil nil D. Insurance Financing Effective November 16, 2023, the Company renewed its third-party liability (“TPL”) insurance policy in Israel with total premiums, taxes and fees for $76,263. A cash down payment of $22,699 was paid on November 16, 2023. Under the terms of the insurance financing, payments of $5,356, which include interest at the rate of 13.99% per annum, are due each month for 10 months commencing on December 16, 2023. Effective December 28, 2023, the Company renewed its D&O insurance policy with total premiums, taxes and fees for $441,598. A cash down payment of $68,733 was paid on December 13, 2023. Under the terms of the insurance financing, payments of $37,287, which include interest at the rate of 13.4% per annum, are due each month for 10 months commencing on January 28, 2024. Effective March 12, 2024, 2024, the Company renewed its rig insurance policy with total premiums, taxes and fees for $94,989. A cash down payment of $37,637 was paid on February 23, 2024. Under the terms of the insurance financing, payments of $9,499, which include interest at the rate of 13.99% per annum, are due each month for 10 months commencing on April 12, 2024. As of June 30, 2024 and December 31, 2023, the Company had contractual obligations to pay for various lines of insurance, including directors and officers, rig and third-party liability. The balances for insurance financing were $232,000 and $432,000, respectively. We haven’t experienced any resistance from our insurance carriers as a result of the Israel-Hamas war, but we acknowledge the uncertainty the war creates in that respect. E. Bank Guarantees As of June 30, 2024, the Company provided Israeli-required bank guarantees to various governmental bodies (approximately $970,000) and others (approximately $89,000) with respect to its drilling operation in an aggregate amount of approximately $1,059,000. The (cash) funds backing these guarantees are held in restricted interest-bearing accounts in Israel and are reported on the Company’s balance sheets as fixed short-term bank deposits – restricted. F. Vendor Concentration The Company’s financial instruments that are exposed to a concentration of credit risk are accounts payable. At June 30, 2024, there were three suppliers that represent 10% or more of the Company’s accounts payable balance. At December 31, 2023, there were three suppliers that represent 10% or more of the Company’s accounts payable balance. G. Risks Market risk is a broad term for the risk of economic loss due to adverse changes in the fair value of a financial instrument. These changes may be the result of various factors, including interest rates, foreign exchange rates, commodity prices and/or equity prices. In the normal course of doing business, we are exposed to the risks associated with foreign currency exchange rates and changes in interest rates. Foreign Currency Exchange Rate Risks. Interest Rate Risk. The primary objective of our investment activities is to preserve principal while at the same time maximizing yields without significantly increasing risk. To achieve this objective, we invest our excess cash in short-term bank deposits and money market funds that may invest in high quality debt instruments.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 7 - Subsequent Events (i) Approximately $1,797,000 was collected through the Company’s DSPP program during the period July 1 through August 6, 2024. Of this amount, approximately $1,122,000 represents cash received for receivables on our books at June 30, 2024. The difference of $675,000 represents new investments during July and August 2024.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (2,064)	$ (2,334)	$ (3,826)	$ (4,473)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Net Loss per Share Data	A. Net Loss per Share Data Basic and diluted net loss per share of common stock, par value $0.01 per share (“Common Stock”) is presented in conformity with ASC 260-10 “Earnings Per Share.” Diluted net loss per share is the same as basic net loss per share for 2024 as the inclusion of 26,940,575 in stock options and 29,456,952 in warrants would be anti-dilutive. Diluted net loss per share is the same as basic net loss per share for 2023 as the inclusion of 21,286,250 in stock options and 31,701,977 in warrants would be anti-dilutive.
Use of Estimates	B. Use of Estimates The preparation of the accompanying unaudited consolidated condensed financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and the underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of expenses. Such estimates include the valuation of unproved oil and gas properties, deferred tax assets, asset retirement obligations, borrowing rate of interest consideration for leases, accounting and legal contingencies. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity, foreign currency, political instability and energy markets have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the consolidated condensed financial statements in future periods. During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (“COVID-19”). The pandemic significantly impacted the economic conditions in the United States and Israel, as federal, state and local governments reacted to the public health crisis, creating significant uncertainties in the United States, Israel and world economies. In the interest of public health and safety, jurisdictions (international, national, state and local) where we have operations, restricted travel and required workforces to work from home. However, as of the date of this report, most of our employees are working at our physical offices, but have the ability to work from home as needed. Similar uncertainties are posed by the Israel-Hamas war and its duration and whether the war expands regionally to include other hostile parties. It is important to note that Zion’s license area is not located near current combat zone. Actual results may differ from these estimates.
Oil and Gas Properties and Impairment	C. Oil and Gas Properties and Impairment The Company follows the full-cost method of accounting for oil and gas properties. Accordingly, all costs associated with acquisition, exploration and development of oil and gas reserves, including directly related overhead costs, are capitalized. All capitalized costs of oil and gas properties, including the estimated future costs to develop proved reserves, are amortized on the unit-of-production method using estimates of proved reserves. Investments in unproved properties and major development projects are not amortized until proved reserves associated with the projects can be determined or until impairment occurs. If the results of an assessment indicate that the properties are impaired, the amount of the impairment is included in loss from continuing operations before income taxes, and the adjusted carrying amount of the proved properties is amortized on the unit-of-production method. The Company’s oil and gas property represents an investment in unproved properties. These costs are excluded from the amortized cost pool until proved reserves are found or until it is determined that the costs are impaired. All costs excluded are reviewed at least quarterly to determine if impairment has occurred. The amount of any impairment is charged to expense since a reserve base has not yet been established. Impairment requiring a charge to expense may be indicated through evaluation of drilling results, relinquishing drilling rights or other information. During the three and six months ended June 30, 2024, the Company did not record any post-impairment charges. During the three and six months ended June 30, 2023, the Company recorded post-impairment charges of $48,000 and $93,000, respectively. Currently, the Company has no economically recoverable reserves and no amortization base. The Company’s unproved oil and gas properties consist of capitalized exploration costs of $17,815,000 and $16,637,000 as of June 30, 2024 and December 31, 2023, respectively.
Fair Value Measurements	D. Fair Value Measurements The Company follows Accounting Standards Codification (ASC) 820, “Fair Value Measurements and Disclosures,” as amended by Financial Accounting Standards Board (FASB) Financial Staff Position (FSP) No. 157 and related guidance. Those provisions relate to the Company’s financial assets and liabilities carried at fair value and the fair value disclosures related to financial assets and liabilities. ASC 820 defines fair value, expands related disclosure requirements, and specifies a hierarchy of valuation techniques based on the nature of the inputs used to develop the fair value measures. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, assuming the transaction occurs in the principal or most advantageous market for that asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The Company’s financial instruments, including cash and cash equivalents, other receivables. accounts payable and accrued liabilities, are carried at historical cost. At June 30, 2024, and December 31, 2023, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments.
Stock-Based Compensation	E. Stock-Based Compensation ASC 718, “Compensation – Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the consolidated condensed financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity – Based Payments to Non-Employees.” Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.
Warrants	F. Warrants In connection with the Dividend Reinvestment and Stock Purchase Plan (“DSPP”) financing arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are stand-alone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded and accounted as a part of the DSPP investment as additional paid-in capital of the common stock issued. All other warrants are recorded at fair value and expensed over the requisite service period or at the date of issuance, if there is not a service period. Warrants granted in connection with ongoing arrangements are more fully described in Note 3, Stockholders’ Equity
Related parties	G. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. All transactions with related parties are recorded at fair value of the goods or services exchanged. Zion did not have any related party transactions for the periods covered in this report.
Recently Adopted Accounting Pronouncements	H. Recently Adopted Accounting Pronouncements The Company does not believe that the adoption of any recently issued accounting pronouncements in 2024 had a significant impact on our consolidated condensed financial position, results of operations, or cash flow.
Depreciation and Accounting for Drilling Rig and Related Equipment	I. Depreciation and Accounting for Drilling Rig and Related Equipment On March 12, 2020, Zion purchased an onshore oil and gas drilling rig, drilling pipe, related equipment and spare parts for a purchase price of $5.6 million in cash, inclusive of approximately $540,000 allocated in spare parts and $48,000 allocated in additional separate assets. The value of the spare parts and separate assets are captured in separate ledger accounts, but reported as one line item with the drilling rig on the balance sheet. Zion determined that the life of the I-35 drilling rig (the rig Zion purchased), is 10 years. Zion is depreciating the rig on a straight-line basis. Zion uses the First In First Out (“FIFO”) method of accounting for the spare parts, meaning that the earliest items purchased will be the first item charged to the well in which the spare parts gets consumed. It is also noteworthy that various components and systems on the rig will be subject to certifications by the manufacturer to ensure that the rig is maintained at optimal levels. Per standard practice in upstream oil and gas, each certification performed on our drilling rig increases the useful life of the rig by five years. The costs of each certification will be added to the drilling rig account, and our straight-line amortization will be adjusted accordingly. Zion purchased rig spare parts totaling approximately $22,000 during the second quarter of 2024 in preparation for its MJ-01 re-entry project. Zion sold some excess scrap drilling pipe and accessories for approximately $30,000 to a local Israeli party during the second quarter of 2024. This transaction triggered a reduction in Other Drilling Assets, an accumulated depreciation adjustment and a loss on the disposal. See the table below for a reconciliation of the rig-related activity during the quarter ended June 30, 2024: I-35 Drilling Rig & Associated Equipment: Six-month period ended June 30, 2024 I-35 Rig Other Total US$ US$ US$ US$ December 31, 2023 4,591 608 311 5,510 Asset Additions - 22 - 22 Asset Depreciation (318 ) - (96 ) (414 ) Asset Disposals - - (93 ) (93 ) Asset Disposals for Self-Consumption - (8 ) - (8 ) June 30, 2024 4,273 622 122 5,017

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2024
Summary of Significant Accounting Policies [Abstract]
Schedule of Drilling Rig & Associated Equipment	See the table below for a reconciliation of the rig-related activity during the quarter ended June 30, 2024: Six-month period ended June 30, 2024 I-35 Rig Other Total US$ US$ US$ US$ December 31, 2023 4,591 608 311 5,510 Asset Additions - 22 - 22 Asset Depreciation (318 ) - (96 ) (414 ) Asset Disposals - - (93 ) (93 ) Asset Disposals for Self-Consumption - (8 ) - (8 ) June 30, 2024 4,273 622 122 5,017

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity (Tables) [Line Items]
Schedule of Stock Option Transactions	The stock option transactions since January 1, 2024 are shown in the table below: Number of Weighted US$ Outstanding, December 31, 2023 34,091,250 0.23 Changes during 2024 to: Granted to employees, officers, directors and others 200,000 0.07 Expired/Cancelled/Forfeited (250,000 ) 2.31 Exercised (95,675 ) 0.09 Outstanding, June 30, 2024 33,945,575 0.22 Exercisable, June 30, 2024 26,940,575 0.25
Schedule of Warrants Transactions	The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: Warrants Exercise Warrant Outstanding Warrants Warrants Warrants Outstanding ZNWAA $ 2.00 01/31/2025 1,498,804 - - - 1,498,804 ZNWAG $ 1.00 01/08/2024 240,068 - - (240,068 ) - ZNWAM $ 0.05 12/31/2024 4,376,000 - - - 4,376,000 ZNWAQ $ 0.05 12/31/2024 23,428,348 - - - 23,428,348 ZNWAZ $ 0.25 07/17/2024 153,800 - - 153,800 Outstanding warrants 29,697,020 - - (240,068 ) 29,456,952
Schedule of Weighted-Average Fair Value of Options Granted	The following table sets forth information about the weighted-average fair value of options granted to employees and directors during the year, using the Black Scholes option-pricing model and the weighted-average assumptions used for such grants: For the 2024 2023 Weighted-average fair value of underlying stock at grant date $ 0.07 $ 0.06 Dividend yields — — Expected volatility 133 % 136%-137 % Risk-free interest rates 3.97 % 3.87%-3.85 % Expected lives (in years) 5.00 5.00 Weighted-average grant date fair value $ 0.07 $ 0.06
Schedule of Compensation Cost of Warrant and Option Issuances	The following table sets forth information about the compensation cost of warrant and option issuances recognized for employees and directors: For the three months ended June 30, 2024 2023 US$ thousands US$ thousands 109 242 For the six months ended June 30, 2024 2023 US$ thousands US$ thousands 230 656 The following table sets forth information about the compensation cost of warrant and option issuances recognized for non-employees: For the three months ended June 30, 2024 2023 US$ thousands US$ thousands 1 — For the six months ended June 30, 2024 2023 US$ thousands US$ thousands 2 2 For the three months ended June 30, 2024 2023 US$ thousands US$ thousands — — The following table sets forth information about the compensation cost of option issuances recognized for employees and non-employees and capitalized to Unproved Oil & Gas properties: For the six months ended June 30, 2024 2023 US$ thousands US$ thousands — —
Schedule of Warrants with an Expiration	The warrants balances at December 31, 2023 and transactions since January 1, 2024 are shown in the table below: Period of Grant US$ Expiration Date ZNWAA Warrants A,B,E,I March 2013 – December 2014 2.00 January 31, 2025 ZNWAM Warrants C,F,J,K January 2021 – March 2021 0.05 December 31, 2024 ZNWAQ Warrants C,F,J,K June 2021 0.05 December 31, 2024 ZNWAS Warrants D August 2021 – March 2022 0.25 December 31, 2025 ZNWAT Warrants D August – September 2022 0.25 December 31, 2025 ZNWAU Warrants D October – November 2022 0.25 December 31, 2025 ZNWAZ Warrants G,L May – June 2023 .25 July 17, 2024 ZNWBA Warrants H,M November – December 2023 .25 September 14, 2025 A On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year. B On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years. C On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year. On June 16, 2023, the Company extended the expiration date of the Warrants to September 6, 2023. On August 21, 2023, the Company extended the expiration date of the Warrants to October 31, 2023. On October 19, 2023, the Company extended the expiration date of the Warrants to December 31, 2023. D These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025. E On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year. F The warrant exercise price was lowered to $0.05 on December 28, 2022. G On May 15, 2023, the Company announced a new Unit Offering and the related ZNWAZ warrant. H On November 6, 2023 the Company announced a new Unit Offering and the related ZNWBA warrant. I On January 10, 2024, the Company extended the expiration date of the ZNWAA warrant by one (1) year. J On December 18, 2023, the Company extended the expiration date of the ZNWAM and ZNWAQ warrants to March 31, 2024. K On March 23, 2024, the Company extended the expiration date of the ZNWAM and ZNWAQ warrants to December 31, 2024. L On July 19, 2024, the Company issued a termination letter to Equiniti to retire these unexercised warrants. M On May 29, 2024, the Company filed Amendment No. 10 whereby the current unit option was extended to August 31, 2024 and the exercise date and termination date of the related ZNWBA warrants were also extended.
Dividend Reinvestment And Stock Purchase Plan [Member]
Stockholders' Equity (Tables) [Line Items]
Schedule of Warrants Transactions	The following table summarizes information about stock options outstanding as of June 30, 2024: Shares underlying outstanding options (non-vested) Shares underlying outstanding options (fully vested) Range of Number Weighted Weighted Range of Number Weighted Weighted US$ US$ US$ US$ 0.07 7,005,000 9.48 0.07 — — — — — — — — 0.01 5,000 0.20 0.01 — — — — 0.01 20,000 2.18 0.01 — — — — 0.01 130,000 2.76 0.01 — — — — 0.01 50,000 2.76 0.01 — — — — 0.01 60,000 3.05 0.01 — — — — 0.01 200,000 3.14 0.01 — — — — 0.01 40,000 3.50 0.01 — — — — 0.01 70,000 3.76 0.01 — — — — 0.01 25,000 3.76 0.01 — — — — 0.01 30,000 3.92 0.01 — — — — 0.01 4,000 4.02 0.01 — — — — 0.01 25,000 4.77 0.01 — — — — 0.01 35,000 5.47 0.01 — — — — 0.01 150,000 5.64 0.01 — — — — 0.01 35,000 5.77 0.01 — — — — 0.01 75,000 6.77 0.01 — — — — 0.01 200,000 7.14 0.01 — — — — 0.01 300,000 7.30 0.01 — — — — 0.01 10,000 7.42 0.01 — — — — 0.01 500,000 7.77 0.01 — — — — 0.01 55,000 7.80 0.01 — — — — 0.01 960,000 8.05 0.01 — — — — 0.01 75,000 8.37 0.01 — — — — 0.01 10,000 8.43 0.01 — — — — 0.01 795,000 8.49 0.01 — — — — 0.01 25,000 8.77 0.01 — — — — 0.01 10,000 9.43 0.01 — — — — 0.01 895,000 9.48 0.01 — — — — 0.01 25,000 9.77 0.01 — — — — 0.06 50,000 8.77 0.06 — — — — 0.07 125,000 9.77 0.07 — — — — 0.14 240,000 7.80 0.14 — — — — 0.15 3,200,000 7.77 0.15 — — — — 0.15 6,389,325 8.05 0.15 — — — — 0.16 340,000 1.70 0.16 — — — — 0.16 75,000 5.70 0.16 — — — — 0.18 25,000 1.67 0.18 — — — — 0.18 5,155,000 8.49 0.18 — — — — 0.24 25,000 8.34 0.24 — — — — 0.24 118,000 8.37 0.24 — — — — 0.25 50,000 7.42 0.25 — — — — 0.25 363,000 7.42 0.25 — — — — 0.28 25,000 1.43 0.28 — — — — 0.28 25,000 5.43 0.28 — — — — 0.29 25,000 3.21 0.29 — — — — 0.39 1,435,000 7.28 0.39 — — — — 0.59 1,400,000 3.14 0.59 — — — — 0.59 1,600,000 7.14 0.59 — — — — 0.92 350,000 2.76 0.92 — — — — 0.92 550,000 6.77 0.92 — — — — 1.38 105,307 0.76 1.38 — — — — 1.67 405,943 0.50 1.67 — — — — 1.78 25,000 0.43 1.78 — — — — 4.15 25,000 0.25 4.15 0.07 7,005,000 0.07 0.01-4.15 26,940,575 0.25

Unproved Oil and Gas Properti_2

Unproved Oil and Gas Properties, Full Cost Method (Tables)	6 Months Ended
	Jun. 30, 2024
Unproved Oil and Gas Properties, Full Cost Method [Abstract]
Schedule of Unproved Oil and Gas Properties	Unproved oil and gas properties, under the full cost method, are comprised as follows: June 30, December 31, US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 3,185 2,538 Capitalized salary costs 2,495 2,444 Capitalized interest costs 1,418 1,418 Legal and seismic costs, license fees and other preparation costs 10,678 10,198 Other costs 39 39 17,815 16,637
Schedule of Post Impairment of Unproved Oil and Gas Properties	Post Impairment of unproved oil and gas properties comprised as follows: For the three months ended For the six months ended 2024 2023 2024 2023 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs - 44 - 55 Capitalized salary costs - - - - Capitalized interest costs - - - - Legal costs, license fees and other preparation costs - 4 - 38 Other costs - - - - - 48 - 93
Schedule of Changes in Unproved Oil and Gas Properties	Changes in Unproved oil and gas properties during the three and six months ended June 30, 2024 and 2023 are as follows: For the three months ended For the six months ended 2024 2023 2024 2023 US$ US$ US$ US$ Excluded from amortization base: Drilling costs, and other operational related costs 593 82 647 145 Capitalized salary costs 25 26 51 52 Capitalized interest costs - - - - Legal costs, license fees and other preparation costs 254 74 480 198 Other costs - - - - Impairment of unproved oil and gas properties - (48 ) - (93 ) *872 *134 *1,178 *302 * Inclusive of non-cash amounts of approximately $338,000, and $709,000 during the three months ended June 30, 2024, and 2023, respectively * Inclusive of non-cash amounts of approximately $1,002,000, and $806,000 during the six months ended June 30, 2024, and 2023, respectively

Right of Use Lease Assets and_2

Right of Use Lease Assets and Lease Obligations (Tables)	6 Months Ended
	Jun. 30, 2024
Right of Use Lease Assets and Lease Obligations [Abstract]
Schedule of Operating Lease Assets and Liabilities	The table below presents the operating lease assets and liabilities recognized on the balance sheet as of June 30, 2024 and December 31, 2023: June 30, December 31, US$ US$ Operating lease assets $ 891 $ 194 Operating lease liabilities: Current operating lease liabilities $ 183 $ 167 Non-current operating lease liabilities $ 669 $ 24 Total operating lease liabilities $ 852 $ 191
Schedule of Weighted Average Remaining Lease Term and Weighted Average Discount Rate	The Company’s weighted average remaining lease term and weighted average discount rate for operating leases as of June 30, 2024 are: June 30, Weighted average remaining lease term (years) 5.9 Weighted average discount rate 7.7 %
Schedule of Future Minimum Lease Payments	The table below reconciles the undiscounted future minimum lease payments (displayed by year and in the aggregate) under non-cancellable operating leases with terms of more than one year to the total operating lease liabilities recognized on the condensed balance sheets as of June 30, 2024: US$ 2024 118 2025 153 2026 150 2027 147 2028 147 Thereafter 350 Total undiscounted future minimum lease payments 1,065 Less: portion representing imputed interest (213 ) Total undiscounted future minimum lease payments 852

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Going Concern (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) ft²	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) ft²	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)	Sep. 14, 2023 a	Sep. 14, 2023 km²
Nature of Operations, Basis of Presentation and Going Concern [Line Items]
Net loss	$ (2,064)	$ (2,334)	$ (3,826)	$ (4,473)
Accumulated deficit	$ (290,385)		$ (290,385)		$ (286,559)
MJ-01 Project [Member]
Nature of Operations, Basis of Presentation and Going Concern [Line Items]
Area of land | ft²	2,050		2,050
New Megiddo Valleys License [Member]
Nature of Operations, Basis of Presentation and Going Concern [Line Items]
Area of land						75,000	302

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Mar. 12, 2020	Apr. 02, 2018
Summary of Significant Accounting Policies [Line Items]
Common stock, par value (in Dollars per share)	$ 0.01		$ 0.01		$ 0.01		$ 0.01
Diluted net loss per share (in Shares)			26,940,575	21,286,250
Post-impairment charges		$ 48,000		$ 93,000
Capitalized exploration costs			$ 17,815,000		$ 16,637,000
Related equipment and spare parts purchase price						$ 5,600,000
Allocated in spare parts						540,000
Allocated in additional separate assets						$ 48,000
Useful life	5 years		5 years
I-35 Drilling Rig [Member]
Summary of Significant Accounting Policies [Line Items]
Useful life						10 years
Rig Spare Parts [Member]
Summary of Significant Accounting Policies [Line Items]
Purchased of other asset			$ 22,000
Drilling Pipe and Accessories [Member]
Summary of Significant Accounting Policies [Line Items]
Sold of other asset			$ 30,000
Warrant [Member]
Summary of Significant Accounting Policies [Line Items]
Diluted net loss per share (in Shares)			29,456,952	31,701,977

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of Drilling Rig & Associated Equipment $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Property, Plant and Equipment [Line Items]
Balance Beginning	$ 5,510
Asset Additions	22
Asset Depreciation	(414)
Asset Disposals	(93)
Asset Disposals for Self-Consumption	(8)
Balance Ending	5,017
I-35 Drilling Rig [Member]
Property, Plant and Equipment [Line Items]
Balance Beginning	4,591
Asset Additions
Asset Depreciation	(318)
Asset Disposals
Asset Disposals for Self-Consumption
Balance Ending	4,273
Rig Spare Parts [Member]
Property, Plant and Equipment [Line Items]
Balance Beginning	608
Asset Additions	22
Asset Depreciation
Asset Disposals
Asset Disposals for Self-Consumption	(8)
Balance Ending	622
Other Drilling Assets [Member]
Property, Plant and Equipment [Line Items]
Balance Beginning	311
Asset Additions
Asset Depreciation	(96)
Asset Disposals	(93)
Asset Disposals for Self-Consumption
Balance Ending	$ 122

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Part-1 - $ / shares	Jun. 30, 2024	Dec. 31, 2023	Jun. 07, 2023	Apr. 02, 2018
Stockholders’ Equity [Line Items]
Common stock par value	$ 0.01	$ 0.01		$ 0.01
Shares authorized to issue (in Shares)	1,200,000,000	1,200,000,000
Minimum [Member]
Stockholders’ Equity [Line Items]
Shares authorized to issue (in Shares)			800,000,000
Maximum [Member]
Stockholders’ Equity [Line Items]
Shares authorized to issue (in Shares)			1,200,000,000

Stockholders' Equity (Details_2

Stockholders' Equity (Details) - Part-2 - USD ($)

3 Months Ended

6 Months Ended

12 Months Ended

Apr. 01, 2024

Aug. 31, 2023

Dec. 14, 2022

Mar. 21, 2022

Jun. 09, 2021

Jun. 09, 2021

Sep. 15, 2020

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2022

Dec. 31, 2023

Dec. 31, 2021

Apr. 15, 2024

Mar. 15, 2024

Jul. 15, 2023

Jun. 12, 2023

May 16, 2023

Jun. 22, 2022

Jun. 02, 2022

Apr. 02, 2018

Stockholders’ Equity [Line Items]

Shares purchased under option plan (in Shares)

25,000

Share price

$ 0.07

$ 0.07

Fair value of stock options granted (in Dollars)

$ 9,000

Unrecognized compensation cost (in Dollars)

$ 101,000

$ 101,000

Extended termination term

1 year

2 years

Sale of Stock, Description of Transaction

expiration date of February 25, 2021 to February 25, 2023

Exercise price per share

$ 0.25

$ 0.25

Warrant exercise price

$ 0.05

$ 0.25

$ 0.25

Cashflow (in Dollars)

$ 365,000

Termination expiration date, description

the Company extended the termination date of the ZNWAQ warrant from July 15, 2023 to September 6, 2023

Equity issuance cost (in Dollars)

$ 173,000

$ 1,930,000

$ 173,000

$ 115,000

Equity issuance costs (in Dollars)

$ 947,000

$ 1,763,000

Maximum purchase (in Dollars)

$ 10,000,000

Warrant [Member]

Stockholders’ Equity [Line Items]

Extended termination term

2 years

Sale of Stock, Description of Transaction

expiration date of May 2, 2021 to May 2, 2023

Exercise price per share

$ 0.25

$ 0.25

Warrant exercise price

$ 0.25

$ 0.25

$ 0.05

$ 0.25

$ 3

Cashflow (in Dollars)

$ 365,000

Termination expiration date, description

the Company extended the termination date of the ZNWAQ warrant from September 6, 2023 to October 31, 2023

ZNWAE warrants [Member]

Stockholders’ Equity [Line Items]

Extended termination term

2 years

Sale of Stock, Description of Transaction

expiration date of May 1, 2021 to May 1, 2023

Warrant exercise price

$ 1

ZNWAF Warrant [Member]

Stockholders’ Equity [Line Items]

Extended termination term

2 years

Sale of Stock, Description of Transaction

expiration date of August 14, 2021 to August 14, 2023

ZNWAJ Warrant [Member]

Stockholders’ Equity [Line Items]

Extended termination term

1 year

2 years

Sale of Stock, Description of Transaction

expiration date of October 29, 2021 to October 29, 2023.

ZNWAG [Member]

Stockholders’ Equity [Line Items]

Sale of Stock, Description of Transaction

expiration date of January 8, 2023 to January 8, 2024.

ZNWAH [Member]

Stockholders’ Equity [Line Items]

Extended termination term

2 years

ZNWAH Warrants [Member]

Stockholders’ Equity [Line Items]

Sale of Stock, Description of Transaction

expiration date of April 2, 2021 to April 2, 2023.

ZNWAM Warrant [Member]

Stockholders’ Equity [Line Items]

Extended termination term

1 year

Sale of Stock, Description of Transaction

expiration date of July 15, 2022 to July 15, 2023

Exercise price per share

$ 0.05

Warrant exercise price

0.25

$ 0.25

ZNWAP Warrant [Member]

Stockholders’ Equity [Line Items]

Extended termination term

1 year

ZNWAO [Member]

Stockholders’ Equity [Line Items]

Warrant exercise price

0.25

$ 0.25

Warrant One [Member]

Stockholders’ Equity [Line Items]

Termination expiration date, description

the Company extended the termination date of the ZNWAQ warrant from October 31, 2023 to December 31, 2023

Warrant Two [Member]

Stockholders’ Equity [Line Items]

Termination expiration date, description

the Company extended the termination date of the ZNWAQ warrant from December 31, 2023 to March 31, 2024

Warrant Three [Member]

Stockholders’ Equity [Line Items]

Termination expiration date, description

the Company extended the termination date of the ZNWAQ warrant from March 31, 2024 to December 31, 2024

Znwar Warrant [Member]

Stockholders’ Equity [Line Items]

Warrant exercise price

$ 0.25

$ 0.25

Minimum [Member]

Stockholders’ Equity [Line Items]

Percentage of net cash

54%

Maximum [Member]

Stockholders’ Equity [Line Items]

Percentage of net cash

56%

56%

Four Senior Officers and Nine Staff [Member]

Stockholders’ Equity [Line Items]

Stock option plan, exercisable date

not to exceed ten years from the date of grant.

Shares purchased under option plan (in Shares)

175,000

Share price

$ 0.07

$ 0.07

Five Staff Members and One Senior Officer [Member]

Stockholders’ Equity [Line Items]

Stock option plan, exercisable date

vested upon grant and are exercisable through January 4, 2034.

One Staff [Member]

Stockholders’ Equity [Line Items]

Share price

$ 0.01

$ 0.01

One Senior Officer [Member]

Stockholders’ Equity [Line Items]

Shares purchased under option plan (in Shares)

25,000

Share price

0.01

$ 0.01

Fair value of stock options granted (in Dollars)

$ 1,500

One Board [Member]

Stockholders’ Equity [Line Items]

Stock option plan, exercisable date

vested upon grant and are exercisable through January 4, 2034

Fair value of stock options granted (in Dollars)

$ 1,500

Five Senior Officers and One Staff [Member]

Stockholders’ Equity [Line Items]

Stock option plan, exercisable date

vested upon grant and are exercisable through January 4, 2033.

Shares purchased under option plan (in Shares)

175,000

Share price

$ 0.0615

$ 0.0615

Zion [Member]

Stockholders’ Equity [Line Items]

Equity issuance cost (in Dollars)

$ 173,000

Zion [Member] | Minimum [Member]

Stockholders’ Equity [Line Items]

Equity issuance cost (in Dollars)

$ 1,120,000

Common Stock [Member]

Stockholders’ Equity [Line Items]

Share price

1

$ 1

Exercise price per share

0.25

0.25

Warrant exercise price

0.25

0.25

Common Stock [Member] | Warrant [Member]

Stockholders’ Equity [Line Items]

Warrant exercise price

1

1

Common Stock [Member] | ZNWAU Warrants [Member]

Stockholders’ Equity [Line Items]

Warrant exercise price

$ 0.25

$ 0.25

Two Zero Two One Omnibus Incentive Stock Option Plan [Member]

Stockholders’ Equity [Line Items]

Number of shares issued (in Shares)

38,000,000

Options exercisable term

10 years

2021 Equity Omnibus Plan [Member] | One Staff [Member]

Stockholders’ Equity [Line Items]

Stock option plan, exercisable date

vested upon grant and are exercisable through January 4, 2033

Shares purchased under option plan (in Shares)

25,000

Fair value of stock options granted (in Dollars)

$ 11,000

2021 Equity Omnibus Plan [Member] | One Board [Member]

Stockholders’ Equity [Line Items]

Fair value of stock options granted (in Dollars)

$ 1,800

Stockholders' Equity (Details_3

Stockholders' Equity (Details) - Part-3						1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 01, 2024 USD ($)	Sep. 15, 2020	May 29, 2019	Dec. 04, 2018	Apr. 02, 2018 $ / shares	Aug. 06, 2024 USD ($)	Jun. 30, 2024 USD ($) $ / shares $ / item shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares $ / item shares	Jun. 30, 2023 USD ($)	Sep. 14, 2025 $ / shares	Aug. 31, 2024 USD ($)	Jul. 31, 2024 USD ($)	Apr. 15, 2024 $ / shares	Mar. 15, 2024 $ / shares	Jan. 10, 2024	Dec. 31, 2023 $ / shares	Sep. 10, 2023 $ / shares	Jul. 31, 2023 $ / shares	Jul. 17, 2023 $ / shares	Jul. 15, 2023 $ / shares	Jul. 13, 2023 $ / shares	Jun. 28, 2023 $ / shares	Jun. 12, 2023 $ / shares	Dec. 14, 2022 $ / shares	Jun. 22, 2022 $ / shares	Jun. 02, 2022 $ / shares	Mar. 21, 2022	Jun. 29, 2018 $ / shares
Stockholders’ Equity [Line Items]
Tranches termination amount (in Dollars) | $							$ 7,500,000		$ 7,500,000
Additional shares (in Shares) | shares							500		500
Exercise price per share																								$ 0.25			$ 0.25
Warrant exercise price							$ 0.25		$ 0.25																$ 0.05
Warrants received (in Shares) | shares									(500)
Number of days required to receive warrant									90 years
Debt Instrument, Increase (Decrease), Net (in Dollars) | $									$ 50
Automatic monthly investments (in Dollars per Item) | $ / item							50		50
Purchase shares of common stock (in Shares) | shares							50		50
Exercise price per Warrant									$ 0.25
Price per share							$ 50		$ 50
Amount raised under the DSPP program (in Dollars) | $							$ 5,896,000	$ 1,761,000	$ 9,453,000	$ 2,553,000
Stock issuance costs (in Dollars) | $							5,896,000		9,453,000	2,553,000
Equity issuance costs (in Dollars) | $							947,000		1,763,000	$ 173,000
Net cash provided amount (in Dollars) | $							4,949,000		7,690,000
Subscriptions receivable (in Dollars) | $	$ 985,000								985,000
Cash received (in Dollars) | $							$ 1,122,000		$ 1,122,000
Common stock par value					$ 0.01		$ 0.01		$ 0.01								$ 0.01
Subscription price					5
Warrant expiration		2 years	1 year	1 year
Number of share owned (in Shares) | shares									10
Termination expiration date, description									expiration date of the Warrants to December 31, 2023.
ZNWAY [Member]
Stockholders’ Equity [Line Items]
AMI minimum amount (in Dollars) | $									$ 500
OTCQX warrants [Member]
Stockholders’ Equity [Line Items]
Units of option (in Dollars) | $									$ 250
Exercise price per share							0.05		$ 0.05
Warrant exercise price							0.25		$ 0.25
ZNWAV Warrants [Member]
Stockholders’ Equity [Line Items]
Number of share purchased (in Shares) | shares									1
Warrant exercise price							0.05		$ 0.05														$ 0.05
ZNWAY [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							0.05		$ 0.05									$ 0.05
Warrant [Member]
Stockholders’ Equity [Line Items]
Units of option (in Dollars) | $									$ 250
Exercise price per share							$ 0.25		$ 0.25
Warrant exercise price					$ 3									$ 0.25	$ 0.25						$ 0.05					$ 0.25
Investments per unit									$ 50
Additional warrant (in Shares) | shares									(50)
Warrants received (in Shares) | shares									(100)
Purchase shares of common stock (in Shares) | shares							300		300
Expiration term		2 years	1 year													1 year									1 year			1 year
ZNWAY Warrants [Member]
Stockholders’ Equity [Line Items]
Warrants received (in Shares) | shares									(250)
ZNWAW Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price																						$ 0.05
ZNWAX Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price																			$ 0.05
ZNWAK Warrant [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							$ 0.25		$ 0.25
ZNWAZ Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price per share																				$ 0.25
Warrant exercise price							$ 0.25		$ 0.25
Purchase shares of common stock (in Shares) | shares							300		300
OTCQB [Member]
Stockholders’ Equity [Line Items]
Common stock price per share							$ 0.25		$ 0.25
ZNWBA Warrants [Member]
Stockholders’ Equity [Line Items]
Exercise price per share							$ 0.25		0.25
Warrant exercise price														$ 0.25
Investments per unit									$ 50
Automatic monthly investments (in Dollars per Item) | $ / item							50		50
Purchase shares of common stock (in Shares) | shares							50		50
Exercise price									$ 0.25
Automatic Monthly Investments [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							$ 0.25		$ 0.25
Purchase shares of common stock (in Shares) | shares							50		50
Subscription Rights Offering [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price																													$ 3
Proceeds from Issuance Initial Public Offering (in Dollars) | $									$ 3,038,000
Expenses from rights offering (in Dollars) | $									243,000
Minimum [Member]
Stockholders’ Equity [Line Items]
Percentage of net cash																	54%
Minimum [Member] | ZNWAY [Member]
Stockholders’ Equity [Line Items]
AMI minimum amount (in Dollars) | $									$ 100
Extension of Termination Date to August 31, 2024 [Member] | ZNWBA Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							$ 0.25		$ 0.25
Extension of Termination Date to August 31, 2024 [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							0.25		0.25
Investments per unit									$ 50
Common Stock [Member]
Stockholders’ Equity [Line Items]
Units of option (in Dollars) | $									$ 250
Exercise price per share							0.25		$ 0.25
Warrant exercise price							$ 0.25		$ 0.25
Option price units (in Dollars per Item) | $ / item							250		250
Common Stock [Member] | OTCQX warrants [Member]
Stockholders’ Equity [Line Items]
Units of option (in Dollars) | $									$ 250
Common Stock [Member] | Warrant [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							$ 1		$ 1
Additional shares (in Shares) | shares									200
Common Stock [Member] | ZNWAZ Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							0.25		$ 0.25
Automatic Monthly Investments ('' AMI'') Program [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							0.25		0.25
Investments per unit									$ 50
Additional warrants (in Shares) | shares									300
Price per share							50		$ 50
Minimum price per month									$ 50
Automatic Monthly Investments ('' AMI'') Program [Member] | ZNWAY [Member]
Stockholders’ Equity [Line Items]
AMI minimum amount (in Dollars) | $									$ 250
Automatic Monthly Investments ('' AMI'') Program [Member] | ZNWBA Warrants [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							0.25		$ 0.25
Unit Option Program [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							$ 0.25		$ 0.25
Option price units (in Dollars per Item) | $ / item							250		250
ZNWBA Warrants [Member] | Warrant [Member]
Stockholders’ Equity [Line Items]
Purchase shares of common stock (in Shares) | shares							50		50
Subsequent Event [Member]
Stockholders’ Equity [Line Items]
New investment amount (in Dollars) | $													$ 675,000
Subsequent Event [Member] | DSPP Program [Member]
Stockholders’ Equity [Line Items]
Amount collected (in Dollars) | $						$ 1,797,000
Unit Option [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price							$ 0.25		$ 0.25
Forecast [Member]
Stockholders’ Equity [Line Items]
New investment amount (in Dollars) | $												$ 675,000
Forecast [Member] | Extension of Termination Date to August 31, 2024 [Member]
Stockholders’ Equity [Line Items]
Warrant exercise price											$ 0.25

Stockholders' Equity (Details_4

Stockholders' Equity (Details) - Schedule of Stock Option Transactions - Stock Option [Member] - $ / shares	6 Months Ended
	Jun. 30, 2024
Schedule of Stock Option Transactions [Line Items]
Number of shares, Outstanding, Beginning balance	34,091,250
Weighted Average exercise price, Outstanding, Beginning balance	$ 0.23
Number of shares, Granted to employees, officers, directors and others	200,000
Weighted Average exercise price, Granted to employees, officers, directors and others	$ 0.07
Number of shares, Expired/Cancelled/Forfeited	(250,000)
Weighted Average exercise price, Expired/Cancelled/Forfeited	$ 2.31
Number of shares, Exercised	(95,675)
Weighted Average exercise price, Exercised	$ 0.09
Number of shares, Outstanding, Ending balance	33,945,575
Weighted Average exercise price, Outstanding, Ending balance	$ 0.22
Number of shares, Exercisable	26,940,575
Weighted Average exercise price, Exercisable	$ 0.25

Stockholders' Equity (Details_5

Stockholders' Equity (Details) - Schedule of Stock Options Outstanding	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.07
Number Outstanding (in Shares) | shares	7,005,000
Weighted average remaining contractual life (years)
Weighted Average Exercise price	$ 0.07
Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number Outstanding (in Shares) | shares	26,940,575
Weighted average remaining contractual life (years)
Weighted Average Exercise price	$ 0.25
Minimum [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	0.01
Maximum [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	4.15
Ranges One [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.07
Number Outstanding (in Shares) | shares	7,005,000
Weighted average remaining contractual life (years)	9 years 5 months 23 days
Weighted Average Exercise price	$ 0.07
Ranges One [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Ranges Two [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Two [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	5,000
Weighted average remaining contractual life (years)	2 months 12 days
Weighted Average Exercise price	$ 0.01
Ranges Three [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Three [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	20,000
Weighted average remaining contractual life (years)	2 years 2 months 4 days
Weighted Average Exercise price	$ 0.01
Ranges Four [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Four [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	130,000
Weighted average remaining contractual life (years)	2 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Five [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Five [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	2 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Six [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Six [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	60,000
Weighted average remaining contractual life (years)	3 years 18 days
Weighted Average Exercise price	$ 0.01
Ranges Seven [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Seven [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	3 years 1 month 20 days
Weighted Average Exercise price	$ 0.01
Ranges Eight [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Eight [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	40,000
Weighted average remaining contractual life (years)	3 years 6 months
Weighted Average Exercise price	$ 0.01
Ranges Nine [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Nine [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	70,000
Weighted average remaining contractual life (years)	3 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Ten [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Ten [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 years 9 months 3 days
Weighted Average Exercise price	$ 0.01
Ranges Eleven [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Eleven [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	30,000
Weighted average remaining contractual life (years)	3 years 11 months 1 day
Weighted Average Exercise price	$ 0.01
Ranges Twelve [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twelve [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	4,000
Weighted average remaining contractual life (years)	4 years 7 days
Weighted Average Exercise price	$ 0.01
Ranges Thirteen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirteen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	4 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Ranges Fourteen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourteen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	5 years 5 months 19 days
Weighted Average Exercise price	$ 0.01
Ranges Fifteen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifteen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	150,000
Weighted average remaining contractual life (years)	5 years 7 months 20 days
Weighted Average Exercise price	$ 0.01
Ranges Sixteen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Sixteen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	35,000
Weighted average remaining contractual life (years)	5 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Ranges Seventeen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Seventeen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	6 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Ranges Eighteen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Eighteen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	200,000
Weighted average remaining contractual life (years)	7 years 1 month 20 days
Weighted Average Exercise price	$ 0.01
Ranges Nineteen [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Nineteen [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	300,000
Weighted average remaining contractual life (years)	7 years 3 months 18 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	7 years 5 months 1 day
Weighted Average Exercise price	$ 0.01
Ranges Twenty One [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty One [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	500,000
Weighted average remaining contractual life (years)	7 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Two [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Two [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	55,000
Weighted average remaining contractual life (years)	7 years 9 months 18 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Three [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Three [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	960,000
Weighted average remaining contractual life (years)	8 years 18 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Four [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Four [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	8 years 4 months 13 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Five [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Five [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	8 years 5 months 4 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Six [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Six [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	795,000
Weighted average remaining contractual life (years)	8 years 5 months 26 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Seven [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Seven [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	8 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Eight [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Eight [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	10,000
Weighted average remaining contractual life (years)	9 years 5 months 4 days
Weighted Average Exercise price	$ 0.01
Ranges Twenty Nine [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Twenty Nine [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	895,000
Weighted average remaining contractual life (years)	9 years 5 months 23 days
Weighted Average Exercise price	$ 0.01
Ranges Thirty [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.01
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	9 years 9 months 7 days
Weighted Average Exercise price	$ 0.01
Ranges Thirty One [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty One [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.06
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	8 years 9 months 7 days
Weighted Average Exercise price	$ 0.06
Ranges Thirty Two [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Two [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.07
Number Outstanding (in Shares) | shares	125,000
Weighted average remaining contractual life (years)	9 years 9 months 7 days
Weighted Average Exercise price	$ 0.07
Ranges Thirty Three [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Three [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.14
Number Outstanding (in Shares) | shares	240,000
Weighted average remaining contractual life (years)	7 years 9 months 18 days
Weighted Average Exercise price	$ 0.14
Ranges Thirty Four [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Four [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	3,200,000
Weighted average remaining contractual life (years)	7 years 9 months 7 days
Weighted Average Exercise price	$ 0.15
Ranges Thirty Five [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Five [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.15
Number Outstanding (in Shares) | shares	6,389,325
Weighted average remaining contractual life (years)	8 years 18 days
Weighted Average Exercise price	$ 0.15
Ranges Thirty Six [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Six [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number Outstanding (in Shares) | shares	340,000
Weighted average remaining contractual life (years)	1 year 8 months 12 days
Weighted Average Exercise price	$ 0.16
Ranges Thirty Seven [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Seven [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.16
Number Outstanding (in Shares) | shares	75,000
Weighted average remaining contractual life (years)	5 years 8 months 12 days
Weighted Average Exercise price	$ 0.16
Ranges Thirty Eight [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Eight [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 8 months 1 day
Weighted Average Exercise price	$ 0.18
Ranges Thirty Nine [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Thirty Nine [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.18
Number Outstanding (in Shares) | shares	5,155,000
Weighted average remaining contractual life (years)	8 years 5 months 26 days
Weighted Average Exercise price	$ 0.18
Ranges Fourty [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.24
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	8 years 4 months 2 days
Weighted Average Exercise price	$ 0.24
Ranges Fourty One [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty One [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.24
Number Outstanding (in Shares) | shares	118,000
Weighted average remaining contractual life (years)	8 years 4 months 13 days
Weighted Average Exercise price	$ 0.24
Ranges Fourty Two [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Two [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number Outstanding (in Shares) | shares	50,000
Weighted average remaining contractual life (years)	7 years 5 months 1 day
Weighted Average Exercise price	$ 0.25
Ranges Fourty Three [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Three [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.25
Number Outstanding (in Shares) | shares	363,000
Weighted average remaining contractual life (years)	7 years 5 months 1 day
Weighted Average Exercise price	$ 0.25
Ranges Fourty Four [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Four [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	1 year 5 months 4 days
Weighted Average Exercise price	$ 0.28
Ranges Fourty Five [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Five [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.28
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	5 years 5 months 4 days
Weighted Average Exercise price	$ 0.28
Ranges Fourty Six [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Six [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.29
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 years 2 months 15 days
Weighted Average Exercise price	$ 0.29
Ranges Fourty Seven [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Seven [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.39
Number Outstanding (in Shares) | shares	1,435,000
Weighted average remaining contractual life (years)	7 years 3 months 10 days
Weighted Average Exercise price	$ 0.39
Ranges Fourty Eight [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Eight [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number Outstanding (in Shares) | shares	1,400,000
Weighted average remaining contractual life (years)	3 years 1 month 20 days
Weighted Average Exercise price	$ 0.59
Ranges Fourty Nine [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fourty Nine [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.59
Number Outstanding (in Shares) | shares	1,600,000
Weighted average remaining contractual life (years)	7 years 1 month 20 days
Weighted Average Exercise price	$ 0.59
Ranges Fifty [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifty [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number Outstanding (in Shares) | shares	350,000
Weighted average remaining contractual life (years)	2 years 9 months 3 days
Weighted Average Exercise price	$ 0.92
Ranges Fifty One [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifty One [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 0.92
Number Outstanding (in Shares) | shares	550,000
Weighted average remaining contractual life (years)	6 years 9 months 7 days
Weighted Average Exercise price	$ 0.92
Ranges Fifty Two [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifty Two [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.38
Number Outstanding (in Shares) | shares	105,307
Weighted average remaining contractual life (years)	9 months 3 days
Weighted Average Exercise price	$ 1.38
Ranges Fifty Three [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifty Three [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.67
Number Outstanding (in Shares) | shares	405,943
Weighted average remaining contractual life (years)	6 months
Weighted Average Exercise price	$ 1.67
Ranges Fifty Four [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifty Four [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 1.78
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	5 months 4 days
Weighted Average Exercise price	$ 1.78
Ranges Fifty Five [Member] | Non-vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price
Number Outstanding (in Shares) | shares
Weighted average remaining contractual life (years)
Weighted Average Exercise price
Ranges Fifty Five [Member] | Vested [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price	$ 4.15
Number Outstanding (in Shares) | shares	25,000
Weighted average remaining contractual life (years)	3 months
Weighted Average Exercise price	$ 4.15

Stockholders' Equity (Details_6

Stockholders' Equity (Details) - Schedule of Weighted-Average Fair Value of Options Granted - Employee [Member] - $ / shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Weighted-Average Fair Value of Options Granted [Line Items]
Weighted-average fair value of underlying stock at grant date (in Dollars per share)	$ 0.07	$ 0.06
Dividend yields
Expected volatility	133%
Risk-free interest rates	3.97%
Expected lives (in years)	5 years	5 years
Weighted-average grant date fair value (in Dollars per share)	$ 0.07	$ 0.06
Minimum [Member]
Schedule of Weighted-Average Fair Value of Options Granted [Line Items]
Expected volatility		136%
Risk-free interest rates		3.87%
Maximum [Member]
Schedule of Weighted-Average Fair Value of Options Granted [Line Items]
Expected volatility		137%
Risk-free interest rates		3.85%

Stockholders' Equity (Details_7

Stockholders' Equity (Details) - Schedule of Compensation Cost of Warrant and Option Issuances - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Employees And Directors [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost of warrant and option issuances	$ 109	$ 242	$ 230	$ 656
Non-Employees [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost of warrant and option issuances	1		2	2
Employees and Non Employees [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Compensation cost of warrant and option issuances

Stockholders' Equity (Details_8

Stockholders' Equity (Details) - Schedule of Warrants Transactions - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 14, 2022
Schedule of Warrants Transactions [Line Items]
Exercise Price (in Dollars per share)	$ 0.25	$ 0.05
Outstanding Warrants	29,697,020
Warrants Issued
Warrants Exercised
Warrants Expired	(240,068)
Outstanding Warrants	29,456,952
Warrant Transactions [Member] | ZNWAA [Member]
Schedule of Warrants Transactions [Line Items]
Exercise Price (in Dollars per share)	$ 2
Warrant Termination Date	Jan. 31, 2025
Outstanding Warrants	1,498,804
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Warrants	1,498,804
Warrant Transactions [Member] | ZNWAG [Member]
Schedule of Warrants Transactions [Line Items]
Exercise Price (in Dollars per share)	$ 1
Warrant Termination Date	Jan. 08, 2024
Outstanding Warrants	240,068
Warrants Issued
Warrants Exercised
Warrants Expired	(240,068)
Outstanding Warrants
Warrant Transactions [Member] | ZNWAM [Member]
Schedule of Warrants Transactions [Line Items]
Exercise Price (in Dollars per share)	$ 0.05
Warrant Termination Date	Dec. 31, 2024
Outstanding Warrants	4,376,000
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Warrants	4,376,000
Warrant Transactions [Member] | ZNWAQ [Member]
Schedule of Warrants Transactions [Line Items]
Exercise Price (in Dollars per share)	$ 0.05
Warrant Termination Date	Dec. 31, 2024
Outstanding Warrants	23,428,348
Warrants Issued
Warrants Exercised
Warrants Expired
Outstanding Warrants	23,428,348
Warrant Transactions [Member] | ZNWAZ [Member]
Schedule of Warrants Transactions [Line Items]
Exercise Price (in Dollars per share)	$ 0.25
Warrant Termination Date	Jul. 17, 2024
Outstanding Warrants	153,800
Warrants Exercised
Warrants Expired
Outstanding Warrants	153,800

Stockholders' Equity (Details_9

Stockholders' Equity (Details) - Schedule of Warrants with an Expiration - Investor [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares
ZNWAA Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	March 2013 – December 2014	[1],[2],[3],[4]
Exercise Price	$ 2	[1],[2],[3],[4]
Expiration Date	January 31, 2025	[1],[2],[3],[4]
ZNWAM Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	January 2021 – March 2021	[5],[6],[7],[8]
Exercise Price	$ 0.05	[5],[6],[7],[8]
Expiration Date	December 31, 2024	[5],[6],[7],[8]
ZNWAQ Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	June 2021	[5],[6],[7],[8]
Exercise Price	$ 0.05	[5],[6],[8]
Expiration Date	December 31, 2024	[5],[6],[8]
ZNWAS Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	August 2021 – March 2022	[9]
Exercise Price	$ 0.25	[9]
Expiration Date	December 31, 2025	[9]
ZNWAT Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	August – September 2022	[9]
Exercise Price	$ 0.25	[9]
Expiration Date	December 31, 2025	[9]
ZNWAU Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	October – November 2022	[9]
Exercise Price	$ 0.25	[9]
Expiration Date	December 31, 2025	[9]
ZNWAZ Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	May – June 2023	[10],[11]
Exercise Price	$ 0.25	[10],[11]
Expiration Date	July 17, 2024	[10],[11]
ZNWBA Warrants [Member]
Schedule of Warrants with an Expiration [Line Items]
Period of Grant	November – December 2023	[12],[13]
Exercise Price	$ 0.25	[12],[13]
Expiration Date	September 14, 2025	[12],[13]
[1] On December 14, 2022, the Company extended the expiration date of the Warrants by one (1) year. On January 10, 2024, the Company extended the expiration date of the ZNWAA warrant by one (1) year. On May 29, 2019, the Company extended the expiration date of the Warrants by one (1) year. On September 15, 2020, the Company extended the expiration date of the Warrants by two (2) years. On December 18, 2023, the Company extended the expiration date of the ZNWAM and ZNWAQ warrants to March 31, 2024. On March 21, 2022, the Company extended the expiration date of the Warrants by one (1) year. On June 16, 2023, the Company extended the expiration date of the Warrants to September 6, 2023. On August 21, 2023, the Company extended the expiration date of the Warrants to October 31, 2023. On October 19, 2023, the Company extended the expiration date of the Warrants to December 31, 2023. On March 23, 2024, the Company extended the expiration date of the ZNWAM and ZNWAQ warrants to December 31, 2024. The warrant exercise price was lowered to $0.05 on December 28, 2022. These warrants will be issued and become exercisable beginning on November 15, 2025 and expire on December 31, 2025. On May 29, 2024, the Company filed Amendment No. 10 whereby the current unit option was extended to August 31, 2024 and the exercise date and termination date of the related ZNWBA warrants were also extended. On November 6, 2023 the Company announced a new Unit Offering and the related ZNWBA warrant.

Unproved Oil and Gas Properti_3

Unproved Oil and Gas Properties, Full Cost Method (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Unproved Oil and Gas Properties, Full Cost Method [Abstract]
Non-cash amounts	$ 338,000	$ 709,000	$ 1,002,000	$ 806,000

Unproved Oil and Gas Properti_4

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of Unproved Oil and Gas Properties - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Excluded from amortization base:
Drilling costs, and other operational related costs	$ 3,185	$ 2,538
Capitalized salary costs	2,495	2,444
Capitalized interest costs	1,418	1,418
Legal and seismic costs, license fees and other preparation costs	10,678	10,198
Other costs	39	39
Unproved oil and gas properties, full cost method	$ 17,815	$ 16,637

Unproved Oil and Gas Properti_5

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of Post Impairment of Unproved Oil and Gas Properties - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Excluded from amortization base:
Drilling costs, and other operational related costs		$ 44		$ 55
Capitalized salary costs
Capitalized interest costs
Legal costs, license fees and other preparation costs		4		38
Other costs
Total of post impairment of unproved oil and gas properties		$ 48		$ 93

Unproved Oil and Gas Properti_6

Unproved Oil and Gas Properties, Full Cost Method (Details) - Schedule of Changes in Unproved Oil and Gas Properties - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Excluded from amortization base:
Drilling costs, and other operational related costs		$ 593	$ 82	$ 647	$ 145
Capitalized salary costs		25	26	51	52
Capitalized interest costs
Legal costs, license fees and other preparation costs		254	74	480	198
Other costs
Impairment of unproved oil and gas properties			(48)		(93)
Total unproved oil and gas properties	[1]	$ 872	$ 134	$ 1,178	$ 302
[1] Inclusive of non-cash amounts of approximately $338,000, and $709,000 during the three months ended June 30, 2024, and 2023, respectively

Right of Use Lease Assets and_3

Right of Use Lease Assets and Lease Obligations (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($) ft²	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) ft²	Jun. 30, 2023 USD ($)
Right of Use Lease Assets and Lease Obligations [Line Items]
Lease agreement description			The Company had an option to renew the lease for another five years from February 1, 2024 to January 31, 2029, provided it is not in breach of the agreement, where it is required as well to furnish a notice of intent to exercise the option six months prior to termination of lease, and it furnishes a bank guarantee and insurance confirmation prior to commencement of the option period. The Company exercised the option to renew the lease for another seven years from February 1, 2024 through January 31, 2031, when rent is to be paid on a monthly basis in the base amount of approximately NIS 46,500 per month (approximately $12,400) at the exchange rate in effect on the date of this report and is linked to an increase (but not a decrease) in the CPI.
Operating lease costs	$ 74,000	$ 57,000	$ 149,000	$ 126,000
Operating lease liabilities		57,000	829,000	129,000
Use Rights [Member]
Right of Use Lease Assets and Lease Obligations [Line Items]
Operating lease liabilities	$ 80,000		$ 168,000
Caesarea, Israel [Member]
Right of Use Lease Assets and Lease Obligations [Line Items]
Number of square feet (in Square Feet) | ft²	6,566		6,566

Right of Use Lease Assets and_4

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of Operating Lease Assets and Liabilities - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Operating Lease Assets and Liabilities [Abstract]
Operating lease assets	$ 891	$ 194
Operating lease liabilities:
Current operating lease liabilities	183	167
Non-current operating lease liabilities	669	24
Total operating lease liabilities	$ 852	$ 191

Right of Use Lease Assets and_5

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of Weighted Average Remaining Lease Term and Weighted Average Discount Rate	Jun. 30, 2024
Schedule of Weighted Average Remaining Lease Term and Weighted Average Discount Rate for Operating Leases [Abstract]
Weighted average remaining lease term (years)	5 years 10 months 24 days
Weighted average discount rate	7.70%

Right of Use Lease Assets and_6

Right of Use Lease Assets and Lease Obligations (Details) - Schedule of Future Minimum Lease Payments - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Future Minimum Lease Payments [Abstract]
2024	$ 118
2025	153
2026	150
2027	147
2028	147
Thereafter	350
Total undiscounted future minimum lease payments	1,065
Less: portion representing imputed interest	(213)
Total undiscounted future minimum lease payments	$ 852	$ 191

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)							3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 12, 2024	Feb. 23, 2024	Jan. 28, 2024	Dec. 16, 2023	Dec. 13, 2023	Nov. 16, 2023	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Dec. 28, 2023
Commitments and Contingencies [Line Items]
Accrued license
Total premiums, taxes and fees	$ 94,989					$ 76,263				$ 441,598
Cash down payment		$ 37,637			$ 68,733	$ 22,699
Insurance financing, payments	$ 9,499		$ 37,287	$ 5,356
Rate of interest	13.99%		13.40%	13.99%
Due month	10 months		10 months	10 months
Outstanding amount, insurance financing							$ 232,000	232,000	$ 432,000
Bank guarantees to government							970,000	970,000
Bank guarantees to others							89,000	89,000
Bank guarantee amount							1,059,000	$ 1,059,000
Percentage of currency inflation								3.60%	3.10%
Cash, cash equivalents and short-term bank deposits							$ 3,525,000	$ 3,525,000
Fund interest rate percentage							2.90%	2.80%
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Four Suppliers [Member]
Commitments and Contingencies [Line Items]
Concentration of credit risk								10%
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three Suppliers [Member]
Commitments and Contingencies [Line Items]
Concentration of credit risk								10%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended
	Aug. 06, 2024	Aug. 31, 2024	Jul. 31, 2024	Jun. 30, 2024
Subsequent Events [Line Items]
Cash received				$ 1,122,000
Subsequent Event [Member]
Subsequent Events [Line Items]
New investment amount			$ 675,000
DSPP Program [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Amount collected	$ 1,797,000
Forecast [Member]
Subsequent Events [Line Items]
New investment amount		$ 675,000